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English Summary
Signaltransduction is an important process, that is crucial for the interplay
of cells in multicellular organisms and controls among other things cellu-
lar proliferation and cellular differentiation. The complexity of signalling
networks and the absence of comprehensive and accurate quantitative data
make a precise mathematical description of such networks difficult. This
work deals with the questions, if and how predications about signalling pro-
cesses for specific cellular models can be made with the aid of interaction
databases and gene expression profiles.
Starting from molecular interaction-databases complex networks are gen-
erated comprising all known cellular signalling paths. But, not all of them
play a role in a specific cellular model. The specific adaptation of the net-
works to a specific cellular system is achieved by additional integration of
data obtained from gene expression profiles. Thereby, 1. the information
about expression or non-expression of a gene and 2. the change of gene
expression in time (increase, decrease or unchanged) is used.
1. Information about the expression is included in the calculations, by
removing unexpressed elements from the network and thus changing
its topology.
2. Chronological changes in expression are integrated in the estimations
by a four-valued, discrete network containing statistical elements, that
was developed in this work. This network is able to deal with contra-
dicting data and pays attention to the importance of feedback loops
for differentiation processes.
This enables an extraction of subnetworks having a dynamic that approx-
imates the measured data best. Hematopoietic processes, playing among
other things a role in development of leukaemias, were examined with a sen-
sitivity analysis. The analysis revealed central molecules of EpoR induced
hematopoesis, like AKT, PIP3, Pi3K, Lyn, ERK.
Deutsche Zusammenfassung
Signaltransduktion ist ein wichtiger Prozess, der fu¨r das Zusammenspiel der
Zellen in mehrzelligen Organismen essentiell ist und u.a. Zellproliferation so-
wie Zelldifferenzierung kontrolliert. Die Komplexita¨t von Signalnetzwerken
und das Fehlen von umfassenden und genauen quantitativen Daten gestal-
ten eine exakte mathematische Beschreibung solcher Netzwerke schwierig.
Diese Arbeit befasst sich mit der Frage, ob und wie mit Hilfe von Interakti-
onsdatenbanken und Genexpressionsprofilen Aussagen u¨ber Signalprozesse
fu¨r spezifische Zellmodelle getroffen werden ko¨nnen.
Ausgehend von Interaktionsdatenbanken werden komplexe Netzwerke
generiert, die alle bekannten Signalwege in den Zellen zusammenfassen. Die-
se spielen jedoch nicht alle in einem spezifischen Zellmodell eine Rolle. Die
spezifische Anpassung der Netzwerke an ein bestimmtes zellula¨res System
erfolgt durch zusa¨tzliche Integration von Daten aus Genexpressionsprofilen.
Dabei werden 1. die Information u¨ber Expression bzw. Nicht-expression ei-
nes Genes, sowie 2. die zeitliche Vera¨nderung der Expression von Genen
(Zunahme, Abnahme oder unvera¨nderte Expression) verwendet.
1. Informationen zur Expression werden durch ein Entfernen der nichtex-
primierten Elemente aus dem Netzwerk beru¨cksichtigt und vera¨ndern
somit die Topologie des Netzwerkes.
2. Zeitliche Vera¨nderungen der Expression werden durch ein in dieser Ar-
beit entwickeltes vierwertiges, diskretes Berechnungsverfahren, welches
auch statistische Elemente entha¨lt, mit Widerspru¨chen zurechtkommt
und die Wichtigkeit von Ru¨ckkoppelung bei Differenzierungsprozessen
beachtet, beru¨cksichtigt.
Dies ermo¨glicht eine Extraktion von Teilnetzwerken, deren Dynamik den
gemessenen Daten am besten entspricht. Mit Hilfe einer Sensitivita¨tsanalyse
wurden Prozesse der Hematopoese untersucht, die u.a. bei der Entstehung
von Leukemien eine Rolle spielen. Dabei konnten zentrale Moleku¨le fu¨r die
EpoR induzierte Hematopoese, wie beispielsweise AKT, PIP3, Pi3K, Lyn,
ERK identifiziert werden.
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Chapter 1
Introduction
Chronic myelogenous leukaemia (CML) is a myeloproliferative malignancy
with clonal expansion of transformed primitive hematopoietic progenitor
cells [1]. It represents 7–20% of all leukemia cases [2] and has an incidence
of 1 to 2 cases per 100000 population [2, 3]. In almost all CML cases (90%)
a chromosomal abnormality called Philadelphia chromosome (Ph) is found
[3, 4]. The abnormality is a reciprocal translocation between the long arms
of chromosomes 9 and 22, which leads to the generation of the BCR-ABL
fusion oncogene and its protein product, the constitutively active BCR-
ABL tyrosine kinase [5, 6]. The abnormal function of this kinase leads to
dysfunctional regulation of cell growth and survival and therefore is sufficient
to cause leukaemia [7, 8, 9].
CML can be treated in several ways [4, 3]:
Allogeneic Stem Cell Transplantation: This therapy is available to on-
ly 40% of the patients. It is the only available therapy with known
curative potential. Stem Cell Transplantation has a treatment related
mortality between 20 to 40% [10].
Chemotherapy: Busulfan is used to control haematologic variables and
thus to reduce the symptoms of CML but it has serious side effects.
Another chemical used in chemotherapy is hydroxyurea, a cell cycle
specific inhibitor of DNA synthesis. Like Busulfan it allows haemato-
logic control but has less side effects. Both chemicals are applied orally.
They can neither produce cytogenic remission, nor delay death, their
effects are mainly palliative.
Interferon-α: IFN can lead to haematologic and cytogenetic remission. Its
effectiveness is increased when it is combined with AraC. The survival
time of patients is increased by this therapy and in 5%–10% of cases
the Philadelphia Chromosome disappears completely. The mechanism
of IFN in CML is poorly understood. IFN therapy is in the long run
not tolerated by 10%–25% of patients.
2Imatinib: Imatinib is a novel agent that specifically inhibits the BCR-
ABL tyrosine kinase. Long-term survival data are not available for
imatinib-treated patients, but data obtained till now suggest that ima-
tinib therapy is more effective and better tolerated than IFN/Ara-C
therapy.
Except Stem Cell Transplantation all therapies work by changing cellular
signalling. This is especially the case for IFN which is targeting the IFN-
Receptor and Imatinib which inhibits specifically the BCR-ABL tyrosine
kinase. Thus a deeper understanding of function of current agents and
discovery of new targets require methods to understand the processes on
the signalling level.
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1.1 Hematopoesis
Hematopoiesis (from Greek haima for blood and poiein to make) is the
development of blood cells. Prenatally hematopoiesis occurs in the yolk
sack, later in liver and spleen. Next, the bone marrow becomes responsible
for hematopoiesis and hematopoiesis in liver and spleen ceases. In normal
adults hematopoiesis occurs in marrow and lymphatic tissues. Although
hematopoietic stem cells are the best studied stem cells in mammals up to
date, [11, 12] some questions still are unanswered or are discussed contro-
versially [11, 13]. Most studies were performed on mice but there are big
parallels between murine and human hematopoietic systems [13].
1.1.1 Differentiation processes
All mature blood cells from T Cells to Neutrophils and platelets are gener-
ated from a small number of hematopoietic stem cells (HSC) and progenitors
[11, 14]. In mice a single HSC is sufficient to rebuild the entire hematopoi-
etic system of an animal [15]. This shows that HSCs can generate a large
number of cells and that they are able to create any cell-type belonging to
the hematopoietic system.
HSCs produce Common Lymphoid Progenitors (CLP) and Common
Multipotent Progenitors (CMP) [16, 17]. This is an irreversible multi-
step process [14]. CLPs and CMPs cannot produce all cell types of the
hematopoietic system any more. CLPs can generate only B, T and NK cells
whereas CMPs have the ability to produce just red cells, platelets, granu-
locytes and monocytes [16, 17]. Figure 1.1 shows natural chemokines that
induce the development of certain progenitors.
For this work it is important to look closer at the differentiation stages
leading to the development of erythrocytes (see also figure 1.1): Hematopoi-
etic stem cells (HSC) are stimulated with TPO and thus differentiate into
common multipotent progenitors (CMP). Stimulation of CMP with EPO
produces megakaryocyte erythrocyte progenitors (MEP) which can further
differentiate to erythroblasts and erythrocytes if they are further stimulated
with EPO. I would like to note that the interplay of cytokines leading to
erythrocytes in reality is much more complex [18].
In addition to their ability to differentiate into mature blood cells, HSC
and other hematopoietic cells are able to remain quiescent, proliferate, dif-
ferentiate, self-renew or undergo apoptosis with these cellular processes de-
pending as well on intrinsic genetic processes as on external factors, like
cytokines, chemokines and others [20, 21, 22].
Hematopoietic cell-fate-decision is explained by the instructional model:
instructional model: The instructional model assumes that the environ-
ment plays the primary role in determining the fate of HSCs and pro-
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Figure 1.1: Normal hematopoietic differentiation and lineage switches
The black lines indicate normal lineage relationships and the responsible
ligands , the thick grey arrows represent induced switches. (These do not
necessarily imply direct transitions.) HSC indicates hematopoietic stem
cell; CLP, common lymphoid progenitor; CMP, common multipotent
progenitor; GMP, granulocyte/macrophage progenitor; MEP,
megakaryocyte erythrocyte progenitor; T, T lymphocyte; B, B lymphocyte;
Mac, macrophage; G, neutrophil granulocyte; Eos, eosinophil, Eb,
erythroblast; E, erythrocyte; Meg, megakaryocyte; P, platelet. Mast cells,
NK cells, and dendritic cells have been omitted from the scheme and
placement of eosinophils is speculative. Note that most of the switches were
observed with transformed cell lines in culture and that the cell type
designations (both before and after the switch) may not accurately reflect
the phenotype of the normal counterparts. Modified from [19]
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genitors, thus environmental factors determine lineage choice and cel-
lular development [23].
1.1.2 Lineage switching
In the last few years a series of studies has indicated that hematopoiesis is
not an irreversible hierarchical process and that cells that were believed to
be developmentally restricted can recover their ability to commit to other
lineages [27, 19, 28]. Figure 1.1 shows a summary of observed changes.
The cells showing this behaviour are mainly transformed and altered cells
but also in normal cells, at least in culture, transdifferentiation has been
observed [29]. It is unknown whether transdifferentiation involves retrodif-
ferentiation to an earlier progenitor or if transdifferentiation occurs directly
between different lineages. Despite the fact that some cells have the ability
to retrodifferentiate, most lineage switches most likely do not involve retrod-
ifferentiation [30, 19]. Lineage switches do not occur in vivo or occur in very
low frequencies under normal conditions [19].
Aforementioned lineage switching has been studied intensively in the
past years. Many studies which were carried out that show, how enforced
transcription factor expression results in lineage plasticity [31, 32, 33, 34,
35, 36, 37, 38].
1.1.3 CML
As already mentioned in the introduction CML is caused by the BCR-Abl
fusion oncogene. Three main BCR-Abl isoforms are known p190Bcr−Abl,
p210Bcr−Abl and p230Bcr−Abl, each leading to a different disease phenotype
[39]. Classical CML is associated with p210Bcr−Abl [40].
The p210Bcr−Abl isoform leads to an increase in transformed granulocytic
and megakaryocytic lineages. The majority of cells is arrested at intermedi-
ate stages of differentiation, but a small proportion of cells become mature
neutrophils, eosinophils and basophils [41].
In addition to this rather macroscopic observation transformed cells also
have some altered characteristics on the cellular level [42], which are known.
Activation of Mitogenic Signalling Pathways: In Bcr-Abl transfect-
ed cell lines increased activity of pathways having mitogenic potential
is observed. For example Ras, MAP Kinase, PI-3/Akt Kinase, Myc
and STAT5 pathways get influenced by Bcr-Abl [43, 42].
Inhibition of Apoptosis: It is discussed controversially whether Bcr-Abl
inhibits apoptosis or not in vivo. However, transfection with exogenous
BCR-ABL leads to immortality against growth factor withdrawal and
increased resistance to apoptosis, induced by DNA-damaging agents.
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Proteasomal Degradation: Bcr-Abl can promote the degradation of pro-
teins via the ubiquitin-proteasomal pathway.
Genomic instability: CML evolves in 3 distinct clinical stages: chronic,
and accelerated phases and blast crisis. This is possible because Bcr-
Abl promotes secondary molecular and chromosomal changes, which
with time increase malignancy of the illness. The reason for this effect
might be the inhibition of apoptosis or the dysregulation of DNA repair
that are induced by Bcr-Abl.
Altered Cellular Adhesion: Healthy Hematopoietic progenitors are held
in position by adhesion within the vicinity of cytokine-secreting cells,
determining their fate (see previous sections). CML cells exhibit re-
duced adhesion and thus receive weaker regulatory signals.
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1.2 Signal transduction – dynamic and general rules
‘In biology, signal transduction is any process by which a
cell converts one kind of signal or stimulus into an other. Pro-
cesses referred to as signal transduction often involve a sequence
of biochemical reactions inside the cell, which are carried out
by enzymes and linked through second messengers. Such pro-
cesses take place in as little time as a millisecond or as long as
a few seconds. Slower processes are rarely referred to as signal
transduction [44].’
Signal transduction occurs within a network, leading sometimes to un-
predictable effects, here are some general principles and effects found in
signalling networks.
Phosphorylation and dephosphorylation: It is possible to control en-
zymatic activity reversibly by phosphorylation and dephosphorylation
[45]. Kinases phosphorylate their downstream molecules whereas phos-
phatases dephosphorylate them [45]. Kinases control primarily the
amplitude of a signal and phosphatases its rate and duration [46].
Second messengers: Second messengers are non protein molecules used
to relay a signal within a cell [47]. They can be synthesized/released
and broken down again in specific reactions by enzymes [47]. Second
messengers are used mainly in case a signal is communicated through
extracellular membrane receptors [48]. Examples for secondary mes-
sengers are: cAMP, cGMP, IP3
Ultrasensitivity and thresholds: Cascades with ultrasensitive stimulus
response amplify signals above a threshold and reduce signals be-
low in an all-or-none manner [49]. These could be very important
for events being binary in nature [49]. This leads naturally to in-
creased robustness against fluctuations [50]. Ultrasensitivity obtained
by multisite-phosphorylation is very robust in contrast to zero-order-
ultrasensitivity [49, 51]. Zero-order-ultrasensitivity is unlikely in most
biological systems [51]. Threshold regulation is used in Drosophila to
prevent inappropriate receptor tyrosine kinase responses to moderate
signalling levels [53].
Random effects Two types of noise are distinguished: Intrinsic and ex-
trinsic noise [54]. Intrinsic noise is based on the fluctuations in molecule
number of a single component due to random birth and decay processes
[55, 54, 56]. Extrinsic noise is the fluctuation imposed on a component
by other network members by changes in reaction rates [54, 56, 57].
Noise in cells is generated primarily by low numbers of molecules. Re-
garding protein generation following rules apply [58, 59]:
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1. Large fluctuations are observed at low transcription and high
translation rates
2. Small fluctuations are observed at high transcription and low
translation rates
3. Maximum external noise is observed at intermediate levels of ex-
pression
Noise is required for cell fate decisions and population heterogeneity
in hematopoietic cells, too [57, 60]. Positive feedback can amplify the
effects of noise and thus create a switch-like response [57, 61].
Noise can be decreased by negative feedback loops, redundancy, regu-
latory checkpoints, or stochastic focusing [62, 63, 58, 64, 65, 66, 67].
Feedback : A feedback loop is a circular chain of interactions. For any
circuit each element exerts an indirect effect to itself, this effect can
be either positive or negative. The indirect self regulation that each
element exerts on itself, is the same for all elements of a feedback
loop. This leads to the definition of the ‘circuit sign’. The circuit
sign depends on the number of negative interactions, if their number
is odd, the circuit is negative, otherwise it is positive [68]. At least one
positive feedback loop is required to generate multistationarity [68].
1.3 Computational approaches
In the past years many methods were used to understand and model cellu-
lar networks. Applied methods range from directed and undirected graphs
[69] over Bayesian, Boolean [70, 71], rule-based [72] and generalized logical
networks [73, 74] to stochastic networks [75] and networks using differential
equations [76, 77, 78, 79].
Stochastic networks and networks based on differential equations require
usually a vast amount of knowledge, therefore these networks are best ap-
plied on well studied small systems, like phages or on separable substructures
of big systems.
Most models using discrete time can be treated as special cases of Dy-
namic Bayesian Networks (DBNs) [80]. Additionally, DBNs have some other
beneficial features:
• They are well suited to deal with stochastic phenomena. This is impor-
tant, because stochastic events seem to play a role in differentiation.
• They are able to deal with noisy data. This is relevant, because gene
expression profiles are generally noisy.
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• They are opening the way for likelihood maximization algorithms and
thus can infer hidden parameters and handle missing data. In the
human system it is very likely that data is not complete at present.
Because of all these reasons I believe that Bayesian networks are suited
well to model differentiation of hematopoietic cells.
1.3.1 Bayesian networks
Figure 1.2: A simple network
This is an acyclic directed graph. The variables (nodes) represent states of
molecules, the directed links represent interactions. Blue links represent
activations and red ones inhibitions. The network is constructed from data
found in the Transpath database (see section: 2.2.1)
Figure 1.2 shows some interactions that are found around the kinase
Pi3K, in a biological database, building a causal network. The network
consists of variables representing the status of molecule species and directed
links between them symbolising interactions. A blue arrow indicates activa-
tion, a red arrow inhibition. The whole structure is called a directed graph.
If there is a link from A to B, then B is called child of A and A is a parent
of B. In Figure 1.2 EpoR is parent of Stat5 and Pi3K. Pi3K is child of EpoR
and Vav.
Bayesian networks are used to calculate conditional probabilities of e-
vents. In the above example a conditional probability statement could be as
follows: ‘If EpoR (A) has an increased activity, then how big is the probabil-
ity that Pi3Ks (B) activity is increased or decreased’ . If it is assumed, that
both molecules are expressed and Stat5 is not saturated etc., then the answer
would be: With a probability of 1 Stat5 has also increased activity. The
above statement can be expressed mathematically as: P (B | A) = (1, 0),
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A = (1, 0), where (1,0) means that the probability for increased activity is
1 and for decreased 0. P (B | A) can be translated into ‘the Probability
distribution over the possible states of B if A is known’. The Fundamental
Rule for probability calculus is:
P (B | A)P (A) = P (A,B)
with P (A,B) being the probability A ∧ B that A and B happen together.
This leads to the Bayes Rule[81] :
P (A | B) = P (B | A)P (A)
P (B)
In the above example it was easy to calculate the probability distribution
of Stat5, if EpoR is known, because in this simplified graph Stat5 has only
EpoR as parent. Things become more complicated for SOS, because it has
two contradicting parents, Pi3K and Grb-2, the conditional probability of
SOS depends on the status of Pi3K as well as on the status of Grb-2 P (SOS |
Grb−2, P i3K). The network in Figure 1.2 would require specification of the
following probabilities to be complete: P (EpoR), P (V av), P (Stat5 | EpoR),
P (Pi3K | EpoR, V av), P (PIP3 | Pi3K), P (SOS,Grb− 2 | Pi3K) [81].
In principle, in Bayesian networks the correlations between variables in
the data are used to calculate required probabilities (and thus the topology)
by calculating the most probable model given the data using the Bayes Rule
[82, 83]:
P (Model | Data) = P (Data |Model)P (Model)
P (Data)
with:
P (Data |Model) =
n∏
i=1
qi∏
j=1
(ri − 1)!
(Nij + ri − 1)!
ri∏
k=1
Nijk!
where P (Model | Data) is the probability, that the model is right, if the
data is given. This is the value that has to be maximised.
P (Data |Model) is basically the product of the probability of observing
child nodes, i in a particular state, k if parents are in some state j [82].
n is the number of measured variables.
q − i is the number of possible combinations of values for the parents of
variable i.
ri is equal to the number of states that are possible for variable i.
Nij is the number of cases in the dataset where parents of the variable i are
in state j.
Nijk is the number of cases in the dataset, where variable i is in state k and
its parents are in state j
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1.3.2 Bayesian networks applied to signalling
Woolf et al. [82] describe how they used Bayesian networks to analyse cell
fate decision in embryonic stem cells, a problem that is similar to the analysis
of differentiation processes in hematopoietic stem cells.
Woolf et al. used
‘49 measurement of phosphorylation states of 28 cellular sig-
nalling proteins along with cell proliferation and differentiation
responses, across a landscape of stimulatory extracellular cy-
tokine cues [82]’
to learn their Bayesian network. In order to get enough data to learn
their network Woolf et al. used a resampling and discretisation approach to
convert a single observation into 1000.
They applied the following simplifications on their model:
1. Data taken at different time points are independent of each other
2. The underlying network can be represented as a directed acyclic graph
3. All nodes have less than four parents and/or children
4. Special nodes, called cue, (biologically these correspond to receptors)
have no parents
5. Special nodes (‘high-level, phenomenological outputs of a system’),
called response, have no children
The second simplification is necessary to maintain logical consistency be-
cause till today no calculus has been developed that can cope with feedback
cycles [82, 81, 84]. The other simplifications are required to limit the search
space and deduce directions.
In their work Woolf et al. use the generated data to explore the search
space of possible element-element connections in order to calculate the most
probable network. The resulting network is represented as a directed graph
that connects the 28 measured proteins (see figure 1.3), the used cues and the
measured phenomenological outputs with each other. Therefore the network
has 38 nodes. Woolf et al. needed approximately two weeks of computing
time on a 64-processor IBM pSeries 655 server for network calculation.
The main biological benefits are that, given the expression data together
with errors, a network explaining the data is derived automatically. This
network could then be used to generate hypotheses helping to select drug
targets [82].
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Figure 1.3: The network used by Woolf et al.
This is the network resulting from the analysis in [82]. The nodes are the
28 + 12 measured proteins, cues and ‘high level, phenomenological
outputs’. The arcs show the calculated interactions between them deduced
from 49 measurement of phosphorylation states of the 28 proteins.
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1.3.3 Bayesian networks and data connection
Bayesian approaches have also been used to infer gene networks [85, 86, 87]
from gene expression data. However in this context it seems to be necessary
to include additional biological information to obtain correct results [88, 89,
90]. Imoto et al. present in [90] a method that allows to integrate virtually
any additional data to Bayesian networks.
In their model Imoto et al. use two parameters to find the optimal so-
lution: The prior probability and the marginal likelihood of the data. They
add the biological data into the prior probability of their model and use the
marginal likelihood to measure the fitness of the model to the microarray
data. The prior probability is calculated by assigning an ‘interaction en-
ergy’ to each known biological fact. Using these set values, calculations are
performed recursively together with the expression data to calculate new
interaction energies. Finally, this procedure leads to an optimal solution.
Imoto et al. have to constrain their search space, otherwise their calcu-
lations are intractable even for moderately sized networks [90]. Therefore
they limit their search space by two extreme scenarios and assume that the
real network is somewhere in between.
• The 1st extreme case is a cyclic network.
• The 2nd extreme case is a strictly hierarchical network.
Imoto et al. apply their method on Saccharomyces cerevisiae gene ex-
pression data. They restrict their analysis to downstream genes of 5 tran-
scription factors. For the analysis they use gene expression data obtained
by disrupting 100 genes.
The biological benefit is, that by adding biological knowledge into the
network, more information from microarray data gets extracted leading to
a more accurately estimated gene network [90].
1.3.4 Dynamic Bayesian Networks
The two mentioned methods avoid cycles and disregard temporal informa-
tion of networks. Dynamic Bayesian networks are believed to be able to deal
with temporal information and feedback loops [80, 91, 92].
In contrast to non-dynamic Bayesian networks, where P (Data |Model)
is calculated neglecting the time-order of the measurements, in Dynamic
Bayesian Networks the time-order is not ignored, this allows to some ex-
tent to use time as an additional dimension to transform cyclic networks
into acyclic ones [80]. The incorporation of time is obtained by a statis-
tical analysis of data across different time slices. This means for example
that in a Dynamic Bayesian Network a check is done, whether a relation
between A and B exists for A(t=1)and B(t=1), A(t=1) and B(t=2),A(t=2)
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and B(t=3),A(t=1) and B(t=3) etc.. In contrast to this in non-dynamic
Bayesian networks only relations in data of the kind A(t=1)and B(t=1),
A(t=2) and B(t=2) etc. are considered.
Perrin at al. and Zou et al. analysed gene networks with dynamic
Bayesian networks [91, 92]. Perrin et al. examine S.O.S DNA Repair in
E.coli, they use a time series of 8 genes to learn their model. The time series
consists of 50 measurement points performed in 6 minutes intervals. Zou
et al. model yeast cell cycle with 16 time points done in time intervals of 10
minutes. The network is restricted to 9 transcription factors and 116 genes,
that are regulated by these transcription factors.
Using prior information the model of Zou et al. is able to identify 46 cor-
rect relationships and 1 misdirected. Without prior knowledge their model
identifies 17 relationships and 3 misdirected ones. Zou et al. do not mention
in their publication how many relationships are missed but if every gene is
regulated by a single transcription factor then there should be 116 inter-
actions in the network. Thus most likely even with prior knowledge more
than half of the interactions are missed, although the examined network is
comparatively small.
Zou et al. claim ,that the methods predicts gene-gene relationships more
accurate than traditional Bayesian Network methods [92].
1.4 Aim of the work
The described works of current approaches have some common properties.
• The data and Bayes rule is mainly used to deduce the complete topol-
ogy of the network. This is done even in the work of Imoto et al., where
prior biological knowledge is used to calculate prior probabilities of the
models.
• The treated systems are rather small. Either they deal only with a
fixed number of pre-selected molecules or with a handful transcription
factors and their associated genes and still require a lot of data to
calculate results.
• The models avoid cyclic structures either by not allowing them or by
making them acyclic, using time, despite the fact that feedbacks are
considered to be very important for differentiation processes [93, 94].
• Most models deal with gene networks and disregard interactions on
protein-protein level. The only exception is the work by Woolf et al.,
where phosphorylation events are measured to build a signalling net-
work [82]
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For analysis of Epo induced differentiation in stemcells affymetrix data
for four different time points are available. The chip is able to measure
approximately 33000 genes. The number of genes and thus the number of
possible networks is too big to be feasible with above mentioned methods.
Using the transpath database and restricting the network solely to elements
being downstream of the erythropoietin receptor reduces the network to a
network of approx. 1000 elements. This network is still more than eight
times larger than the biggest networks described above and additionally has
a much more complex structure (see fig. 1.4). In mentioned works the
number of different measured points varied from 16 [92] to 100 [90], which
is 4 to 25 times more data points than those that are available for the task
at hand. All in all, the methods above require way too many data and
therefore cannot be applied to the task at hand without modifications.
Altogether the main problem is the enormous search space that would
be required if the structure would be deduced from the data. In this work I
will present a method that can be used to describe the regulatory network
underlying erythroid differentiation despite a low number of measurement
points. A model for this requires the following characteristics:
• It does not demand many data points even for big networks to produce
results.
• Because positive feedback cycles seem to be important [73] it must be
able to deal with positive feedback cycles.
• It should not assume in contrast to previous methods, that the relation
between elements remains the same all the time.
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Figure 1.4: EpoR-Network:
This is the network downstream of the EpoR as found in Transpath. Red
arrows represent inhibiting interactions, blue arrows activating reactions and
green arrows interactions between genes and proteins and vice versa. The
network consists out of 983 nodes.
Chapter 2
Formulation of a discrete
model that describes aspects
of signalling dynamic
The main problem with large networks arises from the fact, that the learning
process from data is a NP-complete problem, this means that computation
time increases exponentially with problem size [95]. Therefore the only way
to deal with large networks is to restrict the search space from the beginning.
As prior biological knowledge is available it is logical to use this knowledge
to restrict the system. For this purpose the Transpath database was used,
a database containing many protein-protein interactions on the signalling
level. The knowledge of the database can be represented as a directed graph
(see figure 1.4) having proteins, secondary messengers and other elements as
nodes and their interactions as edges. The edges can be of different types,
e.g. ‘activating’, ‘inhibiting’.
Bayesian networks and biochemical directed graphs represent different
concepts [82], therefore it is necessary to develop a method that allows to
use biological networks together with Bayesian networks. A way how this
can be done is shown in the following sections.
2.1 Dynamic conditions during hematopoietic dif-
ferentiation
Hematopoesis appears to be, at least partly, a probabilistic process: At low
levels of multiple cytokines basal hematopoiesis occurs randomly. Higher
doses of cytokines force the cells to differentiate into a specific way [96].
It is likely that basal hematopoiesis is based on low transcription and high
translation rates of proteins, giving rise to stochastic processes. It is likely
that the m-RNAs of these proteins cannot be detected by Affymetrix chips
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and therefore might be marked as absent. By chance these proteins exceed
a threshold, this leads to a self-sustained increase or stabilisation at higher
level of transcription, and thus to differentiation in a certain direction.
It is known that protein concentration is sensitive to external signals at
intermediate expression levels. This leads to the conclusion that proteins
being responsible for above mentioned bistability could also be controlled
well by cytokines at intermediate expression levels, thus levels below the
threshold. If a protein concentration reaches an intermediate level but is
not favoured by the cytokine, then it is unlikely that it will exceed the
threshold, on the other hand a favoured protein will be supported to exceed
the threshold.
This model also explains why a cell if it reaches a certain state of mat-
uration is developmentally inhibited, despite the presence of cytokines. If
the intermediate expression level cannot be obtained by fluctuation, then
cytokine control is less effective.
To overcome probabilistic behaviour and thus establish a sustained value
above/below a threshold a higher/lower production of the proteins must be
somehow established in a stable way. There are multiple ways to achieve
this:
1. positive feedback loops self-activation, also multistep self-activation
get active if the threshold is exceeded.
(a) A is inhibiting B there-
fore the positive cycle can-
not be established
(b) By chance B exceeds a
threshold value, strength-
ening the feedback cycle
(c) The feedback cycle is so
strong that it prevails de-
spite inhibition
Figure 2.1: Multistep self-activation
2. inhibition of an inhibiting process gets active, if the threshold is ex-
ceeded
3. if the threshold is not reached, then a negative feedback loop gets
active (for a protein that is present at high concentrations but has to
be removed)
4. if the threshold is not reached, then an antagonist protein gets acti-
vated (for a protein that is present at high concentrations but has to
be removed)
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5. sustained positive input of a cytokine keeping the value above a thresh-
old
6. sustained negative input of a cytokine keeping the value below a thresh-
old
All scenarios have one feature in common: they contain linear and/or
cyclic self perpetuating structures. Assuming that hematopoiesis is based on
positive feedback loops, then it is sufficient to examine these self sustaining
structures.
2.2 Formal treatment in a discrete network
Assuming that the Transpath database is complete, it is necessary to iden-
tify all possible self sustaining structure combinations being allowed in the
database and afterwards find those that match the measured data best. In
the subsections below it is described how to solve these problems.
2.2.1 Introduction into the Transpath database
The Transpath database contains information about molecules which play
a role in signal transduction and interactions among them. It focuses on
signalling cascades that aim at transcription factors and hence change ex-
pression. The database Transfac contains information about interactions
between Transcription factors and genes. Both databases used together
make it possible to investigate the interplay between events on the protein
level and events on the genetic level. Transpath version 5.3 has 19023 entries
about molecules, 4989 entries about genes and contains 23062 reactions [97].
The entries are manually curated by experts and hence are reliable.
In the database molecules are connected by reactions with each other.
The reactions connecting them have properties such as ‘activation’, ‘inhi-
bition’, ‘unknown’ and others. In this work the required information was
extracted from the database and was modified to satisfy the needs for mod-
elling. All indirect reactions as well as all reactions that were neither ‘ac-
tivations’ nor ‘inhibitions’ were disregarded, this lead to a directed graph.
As the database distinguishes between orthologues and organism specific
molecules and organisms and the organism specific reactions are not com-
plete, all molecules were substituted by their orthologue to get a network as
complete as possible.
2.2.2 Information content of Affymetrix data
Gene expression results are generally believed not to be very precise, there-
fore the information gained by this data is best treated as discrete entity.
Standard analysis with Microarray Suite from Affymetrix yields easily the
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information whether gene expression of a gene ‘increases’ or ‘decreases’ with
time and whether a certain gene is ‘absent’ or ‘present’ at a certain time
point. As Transpath combined with Transfac contains also information on
how signalling networks influence gene expression, it is obvious to use this
data to fit calculations. But the results obtained by Microarray Suite anal-
ysis can be used in an additional way.
As highly regulated proteins, thus proteins that show high difference in
expression in affymetrix chips, have a high correlation between m-RNA con-
centration and concentration of synthesised proteins (r=0.89) [98], changes
in expression profile can be used to estimate changes in protein concentra-
tions. This is only possible for genes that are controlled at the transcriptional
level. So one might conclude that ‘Protein a has a higher concentration, be-
cause its gene A is higher expressed’, but the conclusion ‘Concentration of
Protein b remains constant, because expression of Gene B is unchanged’
is not allowed, because concentration of b might change, if b is controlled
primarily on the translational and/or post-translational level. Assuming
that higher protein concentration correlates with increased activity of a pro-
tein, with some caution gene expression results can also be used to estimate
events, which occur on the signalling level.
These discrete properties can be used to infer probabilities, if the directed
graph from Transpath is known.
2.2.3 Probability inference on directed graphs
Acyclic graphs
The following abbreviations and symbols will be further supplemented and
used throughout this work:
• For the data obtained by Affymetrix measurements abbreviations are
defined as follows:
IncrExpr : Affymetrix Suite 5.0 indicates, that expression of the gene
is increased.
DecrExpr : Affymetrix Suite 5.0 indicates, that expression of the
gene is decreased.
ABSENT : Affymetrix Suite 5.0 indicates, that gene is not expressed.
If a protein is not expressed, then it is not able to interact, there-
fore molecules produced by these genes were removed from the
network, if not at least one homologue gene was expressed.
PRESENT : Affymetrix Suite 5.0 indicates, that gene is expressed.
Proteins whose genes are expressed remain in the network and
are able to perform all their downstream interactions.
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• For the state of the molecules and genes calculated using Transpath,
the model and Affymetrix data, the used symbolism is given as follows.
Only genes and molecules that were not removed from the network can
be in one of the described states:
0 : The activity of the molecule is not changed.
Rule 1 (Calculating ‘0’) If all parents of the molecule are ‘AB-
SENT’ or have the value ‘0’ themselves and all genes produc-
ing the molecule are neither ‘IncrExpr’ nor ‘DecrExpr’, then the
molecule receives the value ‘0’.
+ : The activity of the molecule in the network gets increased or is
already maximal (e.g. saturation).
Rule 2 (Initialise ‘+’) Proteins encoded by genes with ‘Incr-
Expr’ and molecules which are known to have increased activity
(e.g. by measurements) receive ‘+’ as initial value.
Rule 3 (Calculate ‘+’) ‘+’ is calculated as value for a mole-
cule using the topology of Transpath, if all activating parents have
the value ‘+’ or ‘0’ and all inhibiting parents the value ‘-’ or ‘0’
and at least one parent is either ‘+’ or ‘-’.
- : The activity of the molecule in the network gets decreased or is
already zero (e.g. complete inhibition).
Rule 4 (Initialise ‘-’) Proteins encoded by genes with ‘Decr-
Expr’ and molecules which are known to have reduced activity
receive ‘-’ as initial value.
Rule 5 (Calculate ‘-’) ‘-’ is calculated as value for a molecule
using the topology of Transpath, if all activating parents have the
value ‘-’ or ‘0’ and all inhibiting parents the value ‘+’ or ‘0’ and
at least one parent is either ‘+’ or ‘-’.
Applying these rules to the network shown in figure 2.2 the following
conclusions can be drawn. At the beginning all molecules in the network
are in the state ‘0’. The network is consistent with all rules, but does not
contain much information.
The experiments are performed with a medium, that contains Epo, which
is activating EpoR, thus EpoR is initialised with ‘+’ (rule 2). By applying
rules 1, 3, 5 to the network one obtains EpoR= ‘+’, Vav= ‘0’, Stat5= ‘+’,
Pi3K= ‘+’, PIP3= ‘+’, SOS= ‘-’, Grb-2= ‘0’. It is possible to apply all the
rules easily and straightforward.
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Figure 2.2: Previous network example
This is an acyclic directed graph. The variables (nodes) represent states of
molecules, the directed links represent interactions. Blue links represent
activations and red ones inhibitions. The network is constructed from data
found in the Transpath database (see section: 2.2.1)
This changes, if contradictions are introduced into the network. As an
example let the states of all molecules of the network again be ‘0’ and as-
sume that measurements show ‘IncrExpr’ for EpoR and ‘DecrExpr’ for Vav,
applying rules 2, 4 on the network one gets EpoR= ‘+’ and Vav= ‘-’. Stat5=
‘+’ (rule 3), but the value of Pi3K cannot be calculated with rules 1–5. Pi3K
has in this example a ‘+’ activating parent and a ‘-’ inhibiting parent the
available knowledge is not sufficient to decide which effect is stronger and
thus it is not possible to infer what happens to Pi3K. Activity of Pi3K could
increase, decrease or even not change at all. Because in this example it is
unknown which possibility is more probable it will be assumed that Pi3K
is with the same probability ‘+’ and ‘-’ (the case where activity of Pi3K is
not changed is still included, because ‘+’ and ‘-’ also contain the case that
no change occurs at all).
• Hence some additional rules and an additional symbol have to be in-
troduced to the symbols ‘0’, ‘+’, ‘-’ that are already used to describe
the calculated states of molecules in the network.
uk : The activity of the molecule cannot be calculated exactly, there-
fore it is considered to be 50% ‘+’ and 50% ‘-’.
Rule 6 (Calculate ‘uk’) ‘uk’ is calculated as value for a mole-
cule using the topology of Transpath if:
1. at least one activating parent is ‘+’ and at least one activating
parent is ‘-’.
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2. at least one inhibiting parent is ‘+’ and at least one inhibiting
parent is ‘-’.
3. at least one activating parent is ‘+’ and at least one inhibiting
parent is ‘+’.
4. at least one activating parent is ‘-’ and at least one inhibiting
parent is ‘-’.
Rule 7 (Probabilities ‘uk’) If a molecule receives the value
‘uk’ then two new networks with the same topology are created,
one where the molecule has the value ‘+’ and one where it has
the value ‘-’, the newly generated networks share the probability
equally between each other (see example described below in text).
The previously defined rules 1 – 7 are applied to these generated
networks.
Rule 8 (Probability addition) The final probabilities of the val-
ues of a molecule are calculated by multiplying the value in each
network for the molecule and calculating the sum over all net-
works (see example in text).
Let us return to the example and apply the new rules. With rule 6.1
Pi3K=‘uk’. Following rule 7 the network Pi3K+, where Pi3K receives the
value ‘+’ and the network Pi3K-, where Pi3K=‘-’ are generated. Both
networks have the weight 0.5 and are calculated according to the rules.
Pi3K+ leads to the result EpoR=‘+’, Vav=‘-’, Stat5=‘+’, Pi3K=‘+’, Grb-
2=‘0’, PIP3=‘+’, SOS=‘-’ and Pi3K- calculates to: EpoR=‘+’, Vav=‘-’,
Stat5=‘+’, Pi3K=‘-’, Grb-2=‘0’ ,PIP3=‘-’, SOS=‘+’. The results obtained
by adding the results from Pi3K+ and Pi3K- as described in rule 8 are
shown in table 2.1.
To further clarify rules 7 and 8 let all molecules be ‘0’ and the initial
conditions be: EpoR=‘+’, Vav=‘-’, Grb-2=‘+’. Similar to the previous
example rule 7 leads 1st to construction of the networks Pi3K+ and Pi3K-,
each with the weight 0.5. As SOS=‘uk’ for Pi3K+, Pi3K+ is subdivided into
Pi3K+SOS+, where SOS=‘+’ and Pi3K+SOS-, with SOS=‘-’, the weight
0.5 of Pi3K+ is distributed equally between Pi3K+SOS+ and Pi3K+SOS-
7, thus each network receives a weight of 0.25. The final result obtained by
rule 8 is shown in table 2.2.
The rules and symbolism introduced so far allow to calculate possible
networks together with a probability, given some initial conditions and a
topology.
However, the rules described until now are only applicable to non cyclic
processes and have to be extended to cyclic ones.
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Molecule Result Result Final Probability
Name in Pi3K+ in Pi3K- ‘+’ ‘-’ ‘0’
EpoR ‘+’ ‘+’ 1 0 0
Vav ‘-’ ‘-’ 0 1 0
Stat5 ‘+’ ‘+’ 1 0 0
Pi3K ‘+’ ‘-’ 0.5 0.5 0
Grb-2 ‘0’ ‘0’ 0 0 1
PIP3 ‘+’ ‘-’ 0.5 0.5 0
SOS ‘-’ ‘+’ 0.5 0.5 0
Table 2.1: Simple example for rule 8
Pi3K+ is the network, where Pi3K is set to ‘+’ and Pi3K- is the network,
where Pi3K is set to ‘-’. The values for EpoR, Vav, Stat5 and Grb-2 are
independent from the value of Pi3K, therefore their value is certain
(probability = 1) , for the examined conditions. The values of PIP3 and
SOS are influenced by Pi3K, therefore their values are not certain and are
influenced by the probabilities for Pi3K+ and Pi3K-, in the example it is
assumed, that both networks have the same probability, hence PIP3 and
SOS are half ‘+’ and half ‘-’.
Molecule Result Result Final Probability
Name in Pi3K+ in Pi3K- ‘+’ ‘-’ ‘0’
SOS+ SOS-
EpoR ‘+’ ‘+’ ‘+’ 1 0 0
Vav ‘-’ ‘-’ ‘-’ 0 1 0
Stat5 ‘+’ ‘+’ ‘+’ 1 0 0
Pi3K ‘+’ ‘+’ ‘-’ 0.5 0.5 0
Grb-2 ‘+’ ‘+’ ‘+’ 1 0 0
PIP3 ‘+’ ‘+’ ‘-’ 0.5 0.5 0
SOS ‘+’ ‘-’ ‘+’ 0.75 0.25 0
Table 2.2: More complex example for rule 8
Three networks exist: The network Pi3K+, with a probability of 0.5 , that
is further subdivided into SOS+ and SOS-, with a probability 0.25 each and
the network Pi3K-, with a probability of 0.5. The final probability for
SOS= ‘+’ calculates as follows: (Probability from Pi3K+SOS+) +
(Probability from Pi3K-) = 0.25 + 0.5 = 0.75. The other probabilities are
calculated analogously.
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Figure 2.3: Cyclic directed graph
This network is a modification of the network in figure 2.2. 3 cycles were
introduced by adding the dotted arrows. Assuming that these minimal
cycles play an important role in differentiation, it is logical to search that
cycle constellation, that fits best to the given data.
Cyclic graphs
The rules cannot be applied easily to the network shown in figure 2.3, be-
cause for elements, which are part of a cycle, rule 7 would have to be used
recursively ad infinitum. If positive feedback cycles are the important part
for differentiation then it is sufficient to know which cycles exist and which
do not, then it is enough to do statistics on the probabilities of cycles.
In the figure there are three positive feedback cycles. Cycle 1 and cycle 2
stabilise the value of Pi3K . Therefore either both cycles will stabilise the
value of Pi3K supporting each other or the cycles will compete against each
other. In this case one cycle will force its dynamics on Pi3K, while the other
one can be neglected. The cycle whose effects are dominated by the other
cycle will be called ‘inactive’ and the dominant cycle will be called ‘active’.
Using above definitions it can be seen easily, that the activity state of cycle 2
and cycle 3 are depending on each other.
Rule 9 (Allowed Cycles) 1. An ‘active’ cycle is a cycle consisting of
elements with values strongly determined by values of other elements
forming this cycle and weak coupling to effects outside that cycle.
2. Networks containing cycles that share at least one element are ‘allowed’
to have all cycles set to ‘active’ only if all cycles are supporting each
other. Contradicting cycles being ‘active’ at the same time lead to
a ‘forbidden’ network. NW containing contradicting cycles might be
‘allowed’ if some cycles are ‘inactive’.
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Possibility State of cycle 1 State of cycle 2
allowed ++++ +−−
forbidden ++++ —++
forbidden −—−− +−−
allowed −—−− —++
allowed ++++ inactive
allowed −—−+ inactive
allowed inactive +−−
allowed inactive —++
allowed inactive inactive
Table 2.3: Allowed constellation for cycle 1 and cycle 2
The emphasized symbol represents Pi3K. ++++ for State of cycle 1
means: EpoR= ‘+’, Pi3K= ‘+’, PIP3 = ‘+’ and X= ‘+’, analogously the
order for cycle 2 is Pi3K, SOS, Y. Two active cycles are allowed only if
the common members (here Pi3K) receive the same values in both cycles.
If this is not the case either one cycle is inactive or the constellation is not
allowed.
3. An ‘inactive’ cycle is a cycle having at least one element that is strongly
influenced by dynamics outside of the cycle. These cycles are just
topological cycles but not functional because feedback is corrupted.
Rule 10 (Allowed Networks) The networks created following rule 7 are
valid results if they are ‘allowed’ by rule 9.
Rule 11 (Cyclic Probabilities) Rule 8 is changed slightly to: The final
probabilities of the values of a molecule are calculated by multiplying the value
in each ‘allowed’ network for the molecule and calculating the sum over all
‘allowed networks’. The sum over all probabilities must be 1, therefore the
final results get renormalised.
Cycle 1 and cycle 2 share the protein Pi3K, thus the both positive feedback
cycles can be active only under certain circumstances:
• If cycle 1 is in a state where all its elements have the value ‘+’ then
cycle 2 is either in the state+−− (Pi3K=+, SOS=-,Y=-) or ‘inactive’.
If cycle 2 was in the state−++, then it would counteract cycle 1. Pi3K
would follow the dynamics of the stronger cycle and thus activate it. If
both cycles are equally strong then both cycles are ‘inactive’, because
none determines the dynamic of Pi3K. All possible constellations are
shown in table 2.3:
• Similar are the relations between cycle 2 and cycle 3, the cycles can
only coexist in an activated state in only two constellations, cycle 2 is
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in state− + + and cycle 3 in state + + + or cycle 2 in state + − −
and cycle 3 in state −−−. The allowed states are analogous to those
shown in table 2.3
If one assumes that initially all allowed constellations have the same proba-
bility then using the described logic enables one to create an algorithm that
tries to find the allowed network that explains most observations and that
is self sustaining.
2.3 Computational implementation
To calculate large networks according to rules 1–11 a computer programme
was written. There are multiple ways how this can be done, therefore the
main programme steps are described in this chapter.
Step 1 (Set Default:) Initially all elements of the network have the value
‘0’ and thus do not change the network (rule 1)(see figures 2.4 a, 2.5a).
Step 2 (Initialise with known values:) If gene expression is ‘IncrExpr’
or ‘DecrExpr’ for a certain gene then the value for the gene and the protein
it is encoding is set to ‘+’ or ‘-’ (rules 2, 4) in accordance with the mea-
surement (see also figures 2.4b, 2.5b). The programme stores values of this
network in a vector called (PreviousNet).
Step 3 (Calculate consequences:) The elements having the values ‘+’
or ‘-’ effect their children by inhibiting and activating relationships (rules
3, 5, 6). The update is done by executing the rules derived from the arcs
in the directed graph in the order they are written in a table. The rules
used in the programme are based on rules 3, 5, 6. However, rules 3, 5,
6 had to be modified in such a way that their previous value is taken into
consideration. This is important because it ensures, that a cycle that was
chosen to be ‘inactive’ cannot become ‘active’ by chance.
Thus the rules are modified as follows (examples in figures 2.4b-g, 2.5b,c):
1. Parents having the values ‘unchanged’ do not change the value of their
children (rule 1).
2. If the parent has the value ‘+’ and the relation is activating then:
(a) The child receives the value ‘+’ if the previous value of the child
was ‘0’ or ‘+’.
(b) The child receives the value ‘uk’ if its previous value was ‘-’ or
‘uk’.
3. If the parent has the value ‘+’ and the relation is inhibiting then:
2.3 Computational implementation 28
(a) The child receives the value ‘-1’ if, the previous value of the child
was ‘0’ or ‘-’.
(b) The child receives the value ‘uk’ if its previous value was ‘+’ or
‘uk’.
4. If the parent has the value ‘-’ and the relation is activating then:
(a) The child receives the value ‘-’ if the previous value of the child
was ‘0’ or ‘-’.
(b) The child receives the value ‘uk’ if its previous value was ‘+’ or
‘uk’.
5. If the parent has the value ‘-’ and the relation is inhibiting then:
(a) The child receives the value ’+’ if the previous value of the child
was ‘0’ or ‘+’.
(b) The child receives the value ‘uk’ if its previous value was ‘-’ or
‘uk’.
Execution of these rules leads to a network called ActualNet.
Step 4 (Assign random values to ‘uk’)
After the entire list has been executed the algorithm assigns other values to
the elements having the value ‘uk’ in ActualNet:
1. If the value of the element was ‘0’ in PreviousNet then the element
gets by chance the value ‘+’ or ‘-’. The probability is the same for both
values (figures 2.5d, 2.6a).
2. If the value of the element was ‘+’ or ‘-’ in PreviousNet then the
algorithm checks if the element has at least one parent supporting its
previous value. If such a parent exists, then the element gets the same
value as in PreviousNet (figure 2.5d), otherwise either ‘+’ or ‘-’ gets
assigned randomly to the element. The algorithm contains a factor that
determines the chances. This makes it possible to favour the previous
value. I kept in my calculations the probabilities for ‘+’ and ‘-’ equal.
By assigning values to ‘uk’ elements ActualNet is changed. The programme
remembers to which molecules it assigned random values and also the as-
signed values.
Step 5 (Repeat till no change or stable oscillations occur:) IfActu-
alNet and PreviousNet are not the same and if the system is not showing
constant oscillations (determined by comparing ActualNet with the Ac-
tualNet received ten iterations before) then PreviousNet is set to equal
ActualNet and the algorithm returns to step 3 (see also figure 2.7).
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Step 6 (Scoring against data:) The resulting network is scored against
the measured values. The more values in the network equal the measured
values the better the network (figure 2.8).
Step 7 (Repetition:) The algorithm is repeated multiple times from step 1
to find the networks that get the highest score at step 6.
Scoring for a single measurement point
In step 6 the results, obtained by calculations performed by initialising the
network with the measured data as described under step 2, are again com-
pared with this data. Each value of an expressed protein or gene, that
corresponds to rules 2,4 (step 2) gives one point. The points are added to
receive the score for the complete network. In figure 2.8 an example is given,
under the assumption that measurements show EpoR= ‘+’ and Vav= ‘-’.
2.3.1 Modifications to the algorithm enabling it to cope with
time series
The above algorithm can be used with single measurements but as time series
are available it is useful to change it in such a way that it can compute time
series. For this purpose let us consider the network shown in figure 2.9 and
assume that the observations made with gene chips are those shown in table
2.4. In addition to the information in the table lets assume that it is also
known that EpoR= ‘+’.
As some genes are not expressed initially, they and the proteins they are
producing are removed from the network (see figure 2.9b ). The changes
in expression shown in the second column of table 2.4 are the difference in
gene expression between the second and the first time point so, they occur
after EpoR exerted its effects. Therefore, the network is initialised solely
with EpoR= ‘+’ (see figure 2.10.a) and the simulation is done as described
in the previous chapter (step 1–7).
In bigger networks and especially if the experimentally measured time
points have a large distance to each other, gene effects might be involved
in the process. Therefore, after the 1st stable network has been calculated
all values are set to ‘0’ and the network is then reinitialised with EpoR=
‘+’ and the genes having the values calculated in the previous simulation
(see figure 2.10.c). This recursive procedure is repeated several times. The
results for human cells show that the previous calculation restricts solution
space of the next simulation. Some states can be obtained only by passing
multiple turns of calculations described in the previous section.
After multiple calculations for one time point, the measured changes in
expression are introduced into the calculation (figure 2.11.a). This means
that, after setting all values to ‘0’ the network is initialised with measured
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(a) Initially all molecules have the value ‘0’
(step 1).
(b) Let EpoR be ‘+’. As ‘0’ elements of
the network do not change their children
and because ‘0’ is the default value, those
elements are not shown.
(c) EpoR influences at first the activity of
Stat5 and afterwards the activity of Pi3K
(step 3.2.a).
(d) The results for the next time step
are calculated: Pi3K sets PIP3 to ‘+’
(step 3.2.a)) and SOS to ‘-’ (step 3.3.a).
(e) Normal calculation of consequences
with steps 3.2.a, 3.3.a.
(f) X sets value of EpoR to ‘+’ in a posi-
tive feedback loop (step 3.2.a)). Because X
is supporting the value that EpoR already
has, it is not necessary to change the net-
work.
(g) This is the network state resulting from
EpoR= ‘+’. Stat5, X, Pi3K, PIP3 are also
‘+’ and Y, Grb-2 and SOS get ‘-’.
Figure 2.4: Time Series for Non-Contradicting reactions
Colours have the following meaning: green= ‘0’, blue= ‘+’, red= ‘-’. Core
colour symbolises current value, border colour symbolises previous value of
node
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(a) Initially all molecules have the value ‘0’
(step 1).
(b) Let us assume that observation shows
that EpoR= ‘+’ and Vav= ‘-’. How do the
values of the network change ?
(c) The algorithm recognizes that the in-
puts for Pi3K are contradicting each other,
therefore Pi3K= ‘uk’ (steps 3.2.a , 3.4.b)
(d) As the algorithm cannot calculate the
exact value it assigns a random value to
Pi3K (in this case ‘-’) and stores this de-
cision in a variable (step 4.1) (this is indi-
cated by the red border around Pi3K).
(e) The algorithm calculates the conse-
quences of that assignment (step 3).
(f) The algorithm realizes that EpoR is ‘+’
but should be ‘-’, because of X, therefore
similar to d.), EpoR= ‘uk’ (step 3.4.b.) in
step 4.1 a random value will be assigned
to EpoR. This time series is continued in
figure 2.6
Figure 2.5: Time series for contradicting reactions (Part 1)
Symbols are the same as in the previous figure but ‘uk’= black has been
added. Colours have the following meaning: green= ‘0’, blue= ‘+’, red=
‘-’. Core colour symbolises current value, border colour symbolises previous
value of node
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(a) Continuation of figure 2.5. The algo-
rithm assigns by chance the value ‘+’ to
EpoR and remembers that it decided that
way, as indicated by the blue border around
EpoR (step 4.1). As a result, there is again
a conflict with the value of Pi3K.
(b) The algorithm knows that the value of
Pi3K is not consistent with the entire net-
work but as it also knows that it has already
assigned the value ‘-’ Pi3K by chance (see
figure 2.5 d) it first checks if there is at
least one parent supporting the previous,
randomly assigned value. As Vav supports
the value ‘-’ for Pi3K the algorithm assigns
again ‘-’ to Pi3K (step 4.2) and recognizes
that there is again a conflict with EpoR.
(c) Analogously to b) the algorithm checks
if EpoR has at least one parent support-
ing the value ‘+’. Because this is not the
case it assigns the value ‘-’ to EpoR and
remembers this (step 4.2). As a result of
the changed value for EpoR there is now a
conflict with the previous value of Stat5.
(d) The algorithm assigns a random value
to Stat5 and remembers which value it has
assigned.
(e) The value of Stat5 is not consistent.
Now the algorithm checks, if Stat5 has at
least one parent supporting its previous
value and cannot find one ...
(f) ... therefore it assigns the opposite
value to Stat5 and remembers this. This
time the network is consistent and the al-
gorithm gives this as a result.
Figure 2.6: Time series for contradicting reactions (Part 2)
This example shows how the application of the algorithm handles
contradicting reactions by making cycles ‘inactive’. Pi3K is a common
element between Vav and the cycle EpoR, Pi3K, PIP3, X, EpoR. In b the
algorithm by chance sets the cycle to ‘inactive’, by giving effect of Vav a
higher weight. In c it realises that EpoR= ‘+’ is inconsistent if the cycle is
‘inactive’, therefore the value of EpoR gets changed.
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(a) This is a modified form of figure 2.6 b. EpoR has a parent
supporting its previous value.
(b) As the previous value of EpoR is supported it receives again
the same value. Consequently, the program detects a conflict
with the value of Pi3K. As Pi3K’s previous value is supported
by Vav...
(c) ... the algorithm keeps the previous value of Pi3K and pro-
duces again a conflict with the value of EpoR. Here the algo-
rithm realises that the network in subfigure a) and the network
in subfigure c) are the same and thus stops simulation. The
result is an oscillating network.
Figure 2.7: Time series for an oscillating System
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(a) If experiments show that EpoR= ‘+’ and Vav= ‘-’, then
the programme calculates two solutions
(b) As shown in previous figures, this is one possible solution.
Scoring this solution against the measured results would give
1 point for Vav, because it is ‘-’ in the simulation and in the
observation and 0 points for EpoR because network result and
observation contradict each other.
(c) This is the 2nd possible solution. Here EpoR as well as Vav
have the same values in the simulation and the experiment.
Therefore this solution scores 2 points and thus is better than
the previous one.
Figure 2.8: Scoring resulting networks
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values (in the example, those from table 2.4). The resulting network is
reinitialised and recalculated as described in the previous paragraph (fig-
ure 2.11).
After calculating several results using the algorithm described in the pre-
vious section the unexpressed genes and their proteins are removed from the
network and everything is repeated as described above, till all measurement
points have been inserted.
Throughout the simulations the programme calculates how well com-
puted results agree with the experiments and how many elements of the
network change their value during the simulation. Finally, after multiple
runs were performed that way, the best results, being those with a high
similarity to the experimental data and a low number of changes are stored
for further calculations. An example for three runs is shown in table 2.5.
Time Point Gene Name Observation
Expression Status Difference in Expression
Ge-X ‘PRESENT’ ‘IncrExpr’
1 Ge-Y ‘ABSENT’ No Change in Expression
Ge-Z ‘PRESENT’ ‘DecrExpr’
Ge-X ‘PRESENT’ ‘IncrExpr’
2 Ge-Y ‘ABSENT’ No Change in Expression
Ge-Z ‘ABSENT’ No Change in Expression
Ge-X PRESENT –
3 Ge-Y ABSENT –
Ge-Z PRESENT –
Table 2.4: Example expression data
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(a) Let this be a modified network, consisting of Genes Ge-X, Ge-Y, Ge-Z.
(b) Because Ge-Y is ABSENT (see 2.4) it is removed from the network.
Figure 2.9: Network with genes
Circles represent molecules, squares represent genes. Molecules and genes are
allowed to take the following values ‘+’, ‘-’, ‘uk’, ‘0’. In addition to afore
mentioned values genes can also be ‘PRESENT’ or ‘ABSENT’. ‘ABSENT’ genes
and the proteins they are encoding are removed from network (see b).
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(a) EpoR is ‘+’ as mentioned in the text. The other available information is the difference
in gene expression between 2nd, 1st and 3rd, 2nd experimental time point (see table 2.4).
It is assumed, that signalling effects are faster than effects originating from change in ex-
pression and therefore the network is just initialised with the information on the signalling
level.
(b) Then this is the only possible solution.
(c) The network gets reinitialised with the calculated values. In this case the solution is
still the same as for a). The idea behind this recalculation is that initially the fast signalling
events play an important role and regulate the genes but in the long run the dynamic of
the genes starts to dominate. These calculations show the effects of EpoR. Assuming that
the model does not cover all relevant events, the network is again recalculated but this
time it is reinitialised by the measured difference in expression for t2,t1 (see table 2.4)
This is shown in figure 2.11
Figure 2.10: Network with genes t1
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(a) Table 2.4 shows that Ge-X= ‘IncrExpr’ and Ge-Z= ‘De-
crExpr’. As it is known that EpoR= ‘+’ the network has to
be initialised as shown in the figure. This network can have
multiple solutions. One solution is the one shown in figure 2.9
a. The other three are shown here.
(b) This is the solution obtained if Ge-Z is the dominant factor.
(c) This is the solution obtained if all factors have the same
strength.
(d) As the algorithm decides randomly, this is also a possible
solution.
Figure 2.11: Network with genes t2
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(a) From figure 2.11 different reinitialisation possibilities can be
derived. The 1st one is shown here. This solution will produce
for every timepoint the solution shown in figure 2.9 b) as result.
(b) This is the reinitialisation resulting from figure 2.11 b). As
EpoR is known to have an increased activity and because it is
not a gene it is set to increased although the network computed
decreased as result. The possible outcomes of this network are
all four networks.
(c) This is the reinitialisation resulting from figure 2.11 c). Here
also all four networks are possible results.
(d) This is the reinitialisation resulting from figure 2.11 d).
Here also all four networks are possible results.
Figure 2.12: Initialisation possibilities
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Further analysis of obtained results
From table 2.5 one can see that the 2nd run with 24 points delivers the
network matching best to the data shown in table 2.4. By contrast, the
worst network is the last one. It has the lowest score (just 19) and a high
number of changes in protein values. The 1st run has a score of 21 and just
2 changes. Because of this the network obtained from the 1st and 2nd run
are chosen as good networks for further analysis.
The allowed networks are treated as similar good solutions and the al-
gorithm tries to find common parts in the solution. The calculations are
performed for the entire time (simulation time 1–9) and for the 3 single
intervals (e.g. simulation time 1–3; 4–6; 7–8).
The stability of the values is calculated as the average value of the ob-
served molecule over the observed time. For example, the value stability of
Vav during simulation time 1–9 is calculated as
1 + 1 + 1 + 1 + 1 + 1 + 0 + 0 + 0 = 6
from the 1st run and
6 + 1 + 1 + 1− 1− 1− 1 + 0 + 0 + 0 = 6
from the 1st run added to the 2nd run, leading to the result:
6/18 = 0.3333
As the value 0.333 is low, the calculations for the value of Vav are not
considered very reliable. By contrast, for EpoR this value is 1, therefore, it
is very likely that EpoR has an increased activity over the entire calculated
time. Observing Vav only for the 1st three simulated time points leads to the
reliable solution that Vav= ‘+’ (it calculates as 3+36 = 1). These calculations
are performed for every element for all relevant time periods. All the results
for the example can be found in table 2.6.
Additionally, the correlation coefficients between all molecules and rel-
evant time periods are calculated. These are used to identify relevant re-
actions in the network. For example, in the 2nd run the value of Grb-2
determines the value of Pi3K, therefore, the programme would calculate a
lower importance for the interaction between EpoR and Pi3K: Sometimes,
as is it the case here for all entries, it is not possible to calculate a correlation
coefficient, because the values do not change, in these cases the coefficient
for the entire measurement (in this example 1–9) has been taken, if this is
not possible like in this example for EpoR, a simple factor has been calcu-
lated. Calculation is exemplified for EpoR and Pi3K for the entries in table
2.5. Table 2.7 contains all correlation coefficients for the example.
The programme checks if correlated elements are linked in the graph, if
this is the case it checks if the link has the right properties (e.g. elements
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with a positive correlation coefficient should be linked by an activating reac-
tion, negatively correlated elements should have an inhibiting link). If this
is also the case then the programme assigns the correlation coefficient as a
strength to the link,an example is shown in figure 2.13.
1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1− 1− 1− 1 + 1 + 1 + 1
18
= 0.6666
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2.3.2 Sensitivity analysis on a discrete network
A simplified algorithm was used to estimate the sensitivity of the network
based on change in certain molecules. The main change to the algorithm
described in section 2.3 is, that elements of the network which received the
value ‘uk’ keep this value.
The estimation is based on the following ideas:
• Signal transduction downstream of EpoR is a more linear process,
which is constrained by inhibited elements.
• Only elements which have a direct inhibiting reaction can be inhibited
completely.
• As the inhibition probability is not known it is chosen randomly, by
this process many possible networks are generated.
• The likelihood that an element is important for the real network is
biggest for those elements that are important also for the set of possible
networks.
These assumptions are to some degree in contrast to the cyclic assump-
tions made for the previous sections.
The algorithm is as follows (figures 2.14,reffig:SensitivityAnalysis2 show
how the algorithm is working):
1. Identify genes being ‘ABSENT’ and remove those (and proteins as
described in section 2.2.3) from the network.
2. Make a list, called diakoptic list of elements, which have at least one
inhibiting parent.
3. Define an inhibition probability Prob. for molecules being on the
diakoptic list. Start with 0% inhibition probability and increase it
in 10% steps to 100%.
4. Set the 1st element in the diakoptic list to inhibited and inhibit ran-
domly elements on the diakoptic list with regard to Prob.. Inhibited
elements do not change the values of their children.
5. Calculate the resulting values using the rules from section 2.3 with the
specific modifications.
6. Remember the values for the resulting network.
7. Perform point 5–6, but this time let the element, that was set to
inhibited in point 4, influence its children.
8. Repeat point 4 to 6 1000 times.
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Figure 2.13: Example of calculated data shown in graph
The thickness of the arrows indicates the correlation coefficient between the
two elements connected by the arrow, as long as the reaction favours that
correlation (e.g. if the correlation coefficient is negative and the arc is an
activating arc, then the arrows get a small default value 0,1). The size of
the nodes indicates in how many ‘good’ networks a node receives the
specified value.
9. Calculate the differences (see below) from the stored values and save
them in a file.
10. Go to point 4 and repeat all with the 2nd, 3rd etc. element of di-
akoptic list till all elements were set once to inhibited and once to
not inhibited.
11. Go to point 3 and increase inhibition probability by 10%.
The following values were calculated from the saved data for each element
in the diakoptic list:
Difference in Network Size: This difference is the difference in the num-
ber of molecules still attached to EpoR for the network, where the
tested molecule is inhibited and the size of the network, where this
molecule is not inhibited. This value is than averaged over all 1000
simulations (see step 8).
Difference in Network Behaviour: This distance is defined as follows:
If the observed molecule has another value than ‘uk’ then the difference
is 0. If the value is ‘uk’ then the algorithm creates two new networks,
one where the observed molecule has the value ‘+’ and one network
where it is ‘-’. Both networks are calculated as described previously.
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The results of each molecule for both networks are compared with each
other to calculate this difference. If a molecule is ‘+’ in one calculation
and ‘-’ in the other then the difference of this molecule is one. If the
value of the molecule in one simulation is ‘uk’ and either ‘+’ or ‘-’ in
the other then the difference is 0.5. In all other cases the distance
between the molecules is 0. The distance between two networks, is the
sum of the distances of their molecules. This value is also averaged
over all 1000 simulations.
Summarising the results into a single factor, to rank them
The results of the analysis were summarised by assigning a single numeri-
cal value RF to each molecule in the diakoptic list, as a measure of its
importance.
RFi =
∑100%
Prob=0%
MeanAllProb−Meani,Prob
StdAllProb
RFi: Numerical Value RF for molecule i in diakoptic list
MeanAllProb: Mean Value for the Mean Values of all molecules
in diakoptic list, when the probability of inhibition is Prob.
Meani,Prob: Mean Value for i if inhibition probability is Prob
StdAllProb: Standard Deviation for the mean values of all ele-
ments in diakoptic list, for inhibition probability Prob.
Explanation of results for example
In the example the network shown in figure 2.14a was analysed by applying
the algorithm for sensitivity analysis on it. If expression data was available,
then the network analysed would be changed by removing unexpressed genes
and their corresponding proteins as described in section 2.2.3. For this
example it will be assumed, that all proteins are ‘PRESENT’.
As can be seen easily from figure 2.14a, Vav, Pi3K and SOS will go
into the diakoptic list (step 2). The elements in this list are removed from
the network with a probability Prob, hence 23 = 8 different topologies are
possible. The probability of each topology is depending on the value assigned
to Prob and the examined molecule.
Each single calculation of ‘Difference in Network Size’ and ‘Difference in
Network Behaviour’ requires two networks, one where the treated molecule
is in the network and one where the molecule is removed, the two networks
are compared and this procedure is repeated several times.
For the example it is possible to calculate the exact probabilities. The
results are shown in table 2.8. The algorithm calculates the final values
of ‘Difference in Network Size’ and ‘Difference in Network Behaviour’ by
building the sum of each calculated value for each network and multiplying it
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(a) This is the given network. For illus-
tration purposes the reaction between Ge-
Z and Vav has been changed from an ac-
tivating to an inhibiting reaction. The al-
gorithm puts the elements Pi3K, SOS and
Vav into the diakoptic list (step 2 of al-
gorithm), because each has at least one in-
hibiting parent.
(b) Pi3K is the 1st element in the diakop-
tic list so it is removed 1st (step 4). The
elements SOS and Vav are removed with
probability Prob (also step 4). Here, by
chance, both elements are kept in the net-
work.
(c) The algorithm calculates the resulting
network. EpoR effects only Stat5, Ge-X
and X without Pi3k, all other elements re-
main ‘0’ (step 5). The network remembers
that EpoR influences 3 molecules (step 6).
(d) Pi3K is kept in the network and the
previous calculations are repeated (step 7).
(e) If Pi3K is kept in the network this is the
result. EpoR influences now 10 molecules
and all of them have the value ‘uk’ (black).
Difference in Network Size is calculated
by building the difference between the ele-
ments influenced in c.) and this network,
hence 10−3 = 7. This value is remembered
by the programme. Because Pi3k, the ex-
amined molecule, has also the value ‘uk’,
two new networks are created, one, where
Pi3K is forced to be ‘+’ and one where it is
forced to be ‘-’. These networks are shown
in figure 2.15.
Figure 2.14: Sensitivity analysis (Part 1)
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(a) Pi3K is set to be ‘+’. To ensure that
it does not change its value during the sim-
ulation its upstream reactions are removed
from the network.
(b) This is the result, if Pi3K= ‘+’.
(c) In this network Pi3K is forced to be ‘-’
and it cannot change its value, because all
upstream reactions are removed.
(d) This is the result if Pi3K= ‘-’. The pro-
gramme calculates theDifference in Net-
work Behaviour from this network and
network b) of this figure series. The result
is: 0.5 + 0.5 + 0.5 + 0.5 = 2 from EpoR,
Stat5, Ge-X and X 1+1+1+1+1+1+1 = 7
from PIP3, Ge-Z, Vav, Pi3K, SOS, Y, Grb-
2. Thus the result is 2 + 7 = 9.
(e) One Run is completed and the pro-
gramme returns to point 4, removes Pi3K,
and randomly some other elements from
the diakoptic list and then repeats all
calculations. A network, where also SOS
is removed but Vav is kept is shown here.
This procedure of creating new networks
for Pi3K is repeated 1000 times.
(f) After 1000 networks for Pi3K have been
calculated, the programme averages over all
Differences in Network Size and Dif-
ferences in Network Behaviour. Then
it repeats the entire procedure for the next
element in the diakoptic list, in this ex-
ample it is SOS. If all elements in the list
are treated this way the programme in-
creases the inhibition probability Prob by
10% and repeats everything again.
Figure 2.15: Sensitivity analysis (Part 2)
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Examined Inhibited secondary element Diff. in Diff. in Probability
molecule from diakoptic list N. Size N. Behaviour of Network
Pi3K SOS Vav
- - 3 0 Prob2
Pi3K + - 6 0 (1− Prob) ∗ Prob
- + 4 6 Prob ∗ (1− Prob)
+ + 7 9 (1− Prob)2
- - 0 0 Prob2
SOS + - 3 0 (1− Prob) ∗ Prob
- + 0 0 Prob ∗ (1− Prob)
+ + 3 3 (1− Prob)2
- - 0 0 Prob2
Vav + - 1 4 (1− Prob) ∗ Prob
- + 0 0 Prob ∗ (1− Prob)
+ + 1 5.5 (1− Prob)2
Table 2.8: Explanation for results in example
This table shows Probabilities of the possible networks for each examined
molecule, their ‘Difference in Network Size’ and ‘Difference in Network
Behaviour’. The tables shows, that the Probability of a network shifts to
the 1st network for high Prob-Values and to the 4th network for Prob≈0,
for each examined molecule.
with its probability, for each molecule and each probability. As an example
‘Difference in Network Size’ (DiNS) for Pi3K calculates to (see values in
table 2.8):
DiNSPi3K(Prob) = 3Prob2 + (6 + 4) [(1− Prob)Prob] + 7(1− Prob)2
= −4Prob+ 7
The results obtained this way are shown in figure 2.16. In the example
all final DiNS can be calculated as a linear functions of Prob, in complex
systems this is not necessarily the case (e.g. see figure 3.11).
Initially, when Prob= 0 only the network with the single DiNS= 7 ex-
ists, as Prob increases, this network gets less and less probable, whereas
the probabilities of networks with lower single DiNS increase. If Prob gets
closer to one the network, with missing SOS and Vav, gets more and more
dominant, bringing the single DiNS closer and closer to 3. However, Pi3K
has a high DiNS over the entire range of Prob, as can be seen by comparison
with the DiNS(Prob) of the other molecules, shown in figure 2.16.
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(a) The graphic shows the ‘Difference in Network Size’ in dependence on Prob for Pi3K,
SOS, Vav, as calculated in table 2.8. Pi3K has for all values of Prob the highest ‘Difference
in Network Size’.
(b) The graphic shows the ‘Difference in Network Behaviour’ in dependence on Prob for
Pi3K, SOS, Vav, as calculated in table 2.8.Again, Pi3K receives for almost all values of
Prob the highest Difference.
Figure 2.16: Example graphs
Chapter 3
Applications
The method described in the previous chapter was applied on the well un-
derstood Lytic-Lysogeny decision circle to see if it returns valid results.
Afterwards it was applied on CD34+ an K562 hematopoietic cells treated
with EpoR and it identified some differences in the dynamics of these two
cell lines.
3.1 Application of the algorithm on lytic-lysogeny
decision in phage λ-infected Escherichia coli
cells
The lysis-lysogeny decision is a well understood process, that among others
has been analysed with a stochastic model by Arkin et al. [75]. The stochas-
tic model from Arkin et al. has been transformed into a directed graph and
the algorithm has been applied on it. The directed graph deduced from [75]
is shown in figure 3.1. Arkin et al. state that Cro and N get transcribed
immediately after infection. That is why Gene-Cro and Gene-N were set to
‘+’ for the calculations.
Results of some examples are shown in table 3.1. The calculation shows,
that there are only two stable results :
• One where CI, CI2, Gene-CI are ‘+’ and Cro= ‘-’.
• One solution with CI, CI2, Gene-CI being ‘-’ and Cro= ‘+’.
The state of Gene CI at the 1st time point determines which stable
state will be reached. If fluctuations establish a positive feedback cycle
between CI, CI2 and Gene CI, the population continues on the lysogenic
path (time point 2), else after passing a transient state (time point 2) the
system stabilises at a stage with CI= ‘-’ and Cro= ‘+’ (time point 3), the
lytic path.
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Figure 3.1: Network underlying lysis-lysogeny decision
This network was created, by transforming the ODEs found in [75], into
semantic relations. Boxes, indicate genes, circles indicate molecules, blue
arcs symbolise activating and red arcs inhibiting relations.
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These results coincide well with descriptions found in textbooks:
“Phages have a lytic life cycle in which infection of a host
bacterium is followed by production of a large number of phage
particles, lysis of the cell, and release of the viruses. Some phages
also can exist in lysogenic form, in which the phage genome is
integrated into the bacterial chromosome and is inherited in this
inert, latent form like any other bacterial gene [99].”
“The program for the lysogenic and lytic pathways are so
intimately related that it is impossible to predict the fate of an
individual phage genome when it enters a new host bacterium
. . .
The same pathway is followed in both cases right up to the
brink of decision. Both involve the expression of the immediate
early genes and extension into the delayed early genes. The
difference between them comes down to the question of whether
repressor or Cro will obtain occupancy of the operators [99].”
3.2 CD34+ cells treated with Epo
The programme described in section 2 was used to to analyse how CD34+
cells react on Epo, an natural chemokine inducing differentiation of stem
cells towards erythrocytes (see figure 1.1). Affymetrix time series, consisting
out of four time points, were utilised as data. The 1st time point is the
expression profile of untreated CD34+ cells. The other three time points
are measurements made after Epo was added to the medium. The entire
time course comprises several days.
The data was discredited with Micro Array Suite 5.0 from Affymetrix,
keeping the default parameters. This provided the information, whether a
protein was absent or present and if expression increased or decreased with
time, leading basically to a table similar to table 2.4, consisting of too many
genes to be shown here (interested readers will find more information in
[100]).
The network derived from Transpath was modified by removing ‘AB-
SENT’ genes and proteins, having only ‘ABSENT’ genes encoding them
(figure 2.9).
The first calculations were performed by setting EpoR= ‘+’ and cal-
culating results, similar to figure 2.10. Afterwards, in addition to EpoR
= ‘+’, the differences in expression of the genes were also introduced as
initial values into the calculations, this is analogous to what is shown in
figure 2.10. 30 simulation time points were used and the measured data was
entered equidistantly, leading to a table similar to table 2.5, but consisting
of approx. 900 elements, 30 Sim. Time Points and 1000 Runs.
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Because the resulting networks are large (over 100 elements), just a few
results will be presented. At first some groups of proteins, that have the
same temporal behaviour throughout the entire calculations and thus might
be something like functional modules, will be presented.
Afterwards it will be described how some proteins change their value in
the network, while the cells get more and more mature.
3.2.1 Completely correlated groups of proteins
The analysis reveals 79 groups of molecules having a correlation coefficient
of 1 or -1 during the entire process. Only the groups consisting of 10 or
more components will be described.
AKT1-Group: In this group AKT-1, cyclin A:Cdk1, PKAc, RelA, SRY{p}
and the genes IL-12p40 and ICAM-1 are correlated with each other.
FOXO, Caspase-8, Ci, Ci:CBP, Cos2:Fu:SU:Ci and the gene G6PC
are also correlated to each other and anti correlated to the above men-
tioned molecules. The components PKAc, SRY{p}, RelA, Gene IL-
12p40, Gene ICAM-1, Ci Ci:CBP and Cos2:Fu:Su:Ci are connected
directly with each other. AKT-1, FOXO1 and Gene G6PC are also
connected. Two steps into the neighbourhood of these components
were examined in an attempt to connect all of them. PDK1 that is
not member of the group connects Akt-1 with PKAc. Caspase-8 is
connected to Akt-1 via eNOS-NO.
The model gives the following dynamic for this group: Initially Akt-
1= ‘+’. In the next measured time point it gets ‘-’ to be become ‘+’
again in the last two time points. As the molecules have either the
correlation coefficient 1 or -1, the dynamic of the other molecules in
this group can be deduced easily.
ER-α-Group: This group contains many genes. Grb-2:Sos, PR, R-Smads,
Co-Smads and SOS are positively correlated to each other and neg-
atively correlated to ER-α and the genes it is regulating: c-fos, Ug,
NQO1, PTMA, Oxt, HSP27, SLC9A3R1 and additionally negatively
correlated to NHERF-1, FTase, HePTP, MEK, AML1, RSK, RSK2
and the genes Bcl-2, βARK-1 and IL-2. Almost all of the components
can be linked to each other by adding ERK to this group. The gene
IL-2 has 9 upstream regulators and thus possesses many possibilities
to connect to this group.
ER-α initially is ‘-’, but EpoR turns it to ‘+’ and it keeps this value
all the time the other molecules of this group behave accordingly.
EpoR-Group: A short connection between EpoR and the other elements of
this group could not be found. If there is a connection then it consists
of more than two steps. All the other elements can be connected with
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Figure 3.2: GroupAkt1
The symbolism has been changed from the one in the previous chapter.
Here the colour indicates group membership, molecules which are not part
of the group are black. Boxes stand for ‘-’ and circles for ‘+’. Green
coloured arcs are either transregulations or expressions.
Akt1 and PKAc and their downstream molecules function as a module in
CD34+ cells, they are under influence of PDK1. In K562 cells Akt-1,
PKAc and their downstream molecules do not have the same dynamic any
more.
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Figure 3.3: ErαGroup
In CD34+ cells ERK controls the value of Erα and the other shown
molecules have the same dynamic as Erα. In K562 cells this group still
exists, but the dynamic of MEK, RSK 2, SOS, AML 1, R-Smads,
Co-Smads, gene Bcl-2, IL-2, βARK-1 become independent of the group
dynamic.
each other by Caspase-3. CAD, CAD:ICAD, PITSLRE, Mst2, PRK-2,
Mst1, PKCθ, IKK-α{p}:IKK-β{p}:IKK-γ(2) and Bmx are correlated
to EpoR whereas lamin B1, CaMKIV, 14-3-3τ :PKCθ and PARP are
anti correlated.
The dynamic of the EpoR group is interesting. The EpoR effect gets
initially counteracted and it is after the first expression measurement
when EpoR remains ‘+’ all the time.
Ca2+-Group: This group is completely connected and does not require
any non-group elements for linking. The molecules at the top of the
chain are Ca2+ and PLC. All elements of the group except RICS are
positively correlated.
In most simulations Ca2+ is ‘-’ at the beginning, gets ‘+’ for the next
two measurements and then ‘-’ again for a short time to return to the
value ‘+’. The dynamics might be truly that erratic or it might be
that this group does not play any important role.
talin-Group: In this group all elements are positively correlated to each
other. All elements except Cat-2 are also connected to each other and
talin is at the top of the group. If the non-group element FAK1 gets
added to this set, then all elements are connected with each other,
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Figure 3.4: EpoR-Group
EpoR has the same dynamic in CD34+ cells like the other members of the
group, although I could not find which of the many possible connections is
the responsible one. In K562 cells the dynamic behaviour of this group is
independent of EpoR.
Figure 3.5: Ca2+-Group
The dynamic of the proteins in this group is the same only in CD34+ cells.
In K562 cells the dynamics are decoupled.
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Figure 3.6: talin-Group
This group is found almost unchanged in both cell types.
but as FAK1 influences talin and gets itself influenced from inside the
network by β1-integrin and β3-integrin there is no real top molecule
in this group.
Talin in the simulation is ‘+’ at the beginning, gets ‘-’ between the 1st
and the 2nd measurement point and then gets ‘+’ again.
IL-6-Group: This is a big group consisting of 41 elements, approximately
half of them being genes. At first sight this group appears to consist
of unconnected elements, but most of the group members can be con-
nected easily by adding the non-group element IL10, then, only Gene
HSD17B1 is not connected to the network. Adding Sp1, that is a reg-
ulator of the IL10 Gene and Gene HSD17B1, results into a connected
network. The group consists of correlated and anticorrelated elements.
The image gives an overview of the topology and the group members.
IL is ‘-’ at the beginning. With the 3rd measurement point it gets ‘+’
and remains ‘+’ throughout the differentiation process.
c-Kit-group: It was not possible to connect all elements of this group to
each other within two steps. Half of the elements in this group are
depending on c-Kit and show a +1 correlation to it.
C-Kit is initially ‘-’, but after the 1st expression experiment remains
‘+’ all the time.
IFN-γ-group: Only few elements of the group are connected with each
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Figure 3.7: IL-6-Group
In CD34+ cells IL-10 controls the dynamic of shown genes and proteins. In
K562 cells this group does not exist, leading to the conclusion that dynamic
of other proteins than IL-10 determine the dynamic of parts of this group.
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other.
IFN-γ gets ‘+’ by influence of EpoR and remains activated all the time.
The other parts of this group behave according to their correlation
coefficient.
IFN-β-group: The elements of this group cannot be connected within two
steps.
The elements of this group having a positive correlation to IFN-β are
initially ‘-’ or not expressed. After the last measurement they receive
the value ‘+’.
3.2.2 Investigating the network for distinct timepoints
The dynamic during the 1st four time points, simulating the events taking
place from the initial state until the 1st measured point can be grouped into
distinct groups each having its distinct dynamics.
Big group with 373 elements: The previously described groups IL-6-Group,
c-Kit-group, Ca2+, talin-group, IFN-β-group are part of this subgroup,
hence the temporal behaviour of the positive group members is: ‘+’,
‘+’, ‘+’, ‘+’, in other words the members of this group achieve a value
very fast and do not change it.
• The model calculates, that PU.1 is ‘+’, leading also to a ‘+’ for
the genes Sfpi1, ISG15, Acp5 and IL-12 p40. Pure IL-12 is ‘-’ due
to IL-10 being ‘-’, which is an activator for IL-12 gene expression.
The value ‘-’ of IL-10 can be ascribed to the ‘-’ value of its gene.
PU.1 might be ‘+’ due to the ‘+’ of Sfpi1, leading to PU.1 = ‘+’.
• AP-1 = ‘-’, this leads to a ‘+’ for IL-2, IL-3, IL-5, c-fos, Rbp,
p53, c-myc, SPRR1B, ins-1, GM-CSF and a ‘-’ for IL-12p40. The
molecule responsible for AP-1 = ‘-’ could not be identified. Pos-
sible candidates are c-Jun and Ref-1. ILK can be excluded as
explanation, because it is ‘+’ and is linked with an activating
reaction to AP-1.
• NF-ATp= ‘+’ leads to expression of some previously mentioned
genes, like ILs and GM-CSF. Additionally, expression of ICAM-1
is fostered by NF-ATp. A possible signalling chain explaining the
value of NF-ATp is CD19 - BCR - FCγRIIB - SHIP - PIP2 - IP3
- IP3R - Ca2+ - calcineurin - NF-ATp. All elements in this chain
are ‘+’ and are linked via activating reactions.
EpoR containing group with 81 elements: This group contains the pre-
viously mentioned group IFN-γ-group and EpoR-group. Thus the dy-
namic of positive members is given as ‘-’, ‘+’, ‘+’, ‘+’. In this group
the model identifies among other things the following relations:
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• EpoR gets ‘-’ because SOCS-3= ‘+’.
• PRK2= ‘-’ leads to PDK1= ‘-’.
• JNK3= ‘-’ leads to NF-ATc= ‘+’. NF-ATc sets the values of mul-
tiple genes like Egr3, IL-4 and IFN-γ, all of them being members
of the IFN-γ-group, to ‘+’. Proteins produced by the IFN-γ-
gene lead to a ‘+’ for CRkII via IFNRII= ‘+’. In addition to
this IFN-γ might set STAT3 to ‘+’, that subsequently leads to
CSN2= ‘-’.
Differences between the 1st and 2nd timepoint
Because the network is big the 2nd network will be compared to the 1st one.
• The comparison shows, that EpoR now is ‘+’. The explanation for
this is the ‘+’ of c-Kit, being an upstream molecule of EpoR. The
model cannot calculate the reason for c-Kit= ‘+’, possible candidates
are PKC, SHP-1 or SHP-2. The model is not able to identify clearly
downstream effects of EpoR. This is likely to be explained by the many
possible downstream reactions of EpoR.
• Possibly, EpoR among other things supports NFATp= ‘+’ via Epor -
PLCγ - IP3 - IP3R - Ca2+ - calcineurin - NF-ATp, this might be nec-
essary, because the coupling between CD19 - BCR - FCγRIIB - SHIP
- PIP2 is weak during the 2nd time point, this means the correlation
between the values of these molecules is low.
• Talin receives the value ‘-’ mediated via ‘-’ of Akt-1 -¿ eNOS -¿ NO -
Caspase-3 - FAK1 - talin leads via integrins to ‘-’ of ERK, Abl, CDk2
and IAP. Erk via p70S6K sets PkFB-2= ‘-’, which is also influenced
by Akt-1 and RSK2.
• PKAc= ‘-’ leads among other things to a ‘-’ for HNF-6 and subse-
quently to a ‘-’ for HNF4A and G6pc, additionally, PKAc transforms
via RelA ICAM-1, p53, IL12 p40 and MEFH to ‘-’. The model sug-
gests that PDK1= ‘-’ might be a reason for PKAc= ‘-’. The value of
PDK1 might be influenced by Abl= ‘-’ and PRK2= ‘-’.
Differences between the 2nd and 3rd timepoint
• The difference network shows a positive feedback- cycle consisting of
Abl - PDK1 - AKT-1 - eNOS - NO - Caspase-3 - FAK1 - talin -
integrins - Abl, except Caspase-3 all members of the cycle are ‘+’.
Caspase-3 gets ‘-’ by NO, thus Caspase-3 inhibitory strength on FAK1
gets reduced, because of this the cycle is a positive feedback cycle.
The cycle gets further stabilised by PRK2 - PDK1. This cycle leads
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to Transcription Factor RelA= ‘+’, via PKAc= ‘+’, resulting in ‘+’
of p53, MEFV, IL-12 p40, ICAM-1.
• Epo= ‘+’.
• STAT3= ‘-’. The inhibition is done by IL-6, experiencing a ‘+’ ex-
pression during the observed time. STAT3= ‘-’ is further supported
by PKR.
• AP-1= ‘+’, resulting in IL-4 and GM-CSF = ‘+’. The model is not
able to identify the source of Ap-1= ‘+’. Possible sources are IL-12 p40
and Ref-1.
Differences between the 3rd and 4th timepoint
• Jak2= ‘+’ and Jak1= ‘-’ results among other things in STAT6= ‘+’
and STAT5= ‘+’. The model is not able to give a clear answer on why
Jak1 is ‘+’, possible candidates being able to perform this task are: IL-
10R, IFNRI, IL-2R complexes and other receptors. The calculations
suggest a role of CTLA-4, InsR and SOCS-3= ‘+’ in transforming
Jak2 to ‘+’.
• The calculations identify a network starting from PIP2= ‘-’, that con-
nects via IP3 to the absolutely correlated network, called Ca2+-Group
initially. This group interacts with elements of the IFN-β-group via
NF-ATp and Rac1, leading to the speculation that the IFN-β-group
might be a subgroup of the Ca2+-Group..
3.3 K562 cells treated with Epo
3.3.1 Completely correlated groups of molecules
Analogously to the treatment of CD34+ cells , absolutely correlated subsets
of elements in K562 cells were found and afterwards compared to the results
of CD34+ cells. The AKT1, Ca2+-Group, IL-6-Group, c-Kit-Group, IFN-
γ-Group, IFN-β-Group cannot be found in K562 cells.
ER-α-Group: In K562 cells this group is smaller than for CD34+ cells.
The elements MEK, RSK2, SOS, AML1, R-Smads, Co-Smads and the
genes Bcl-2, IL-2 , βARK-1 are missing.
EpoR-Group: EpoR itself is not element of this group any more but gel-
solin and α-fodrin get added to this group.
talin-Group: This group is almost similar to that one found in CD34+
cells. Still one molecule FAK1 cannot be found in this group.
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Figure 3.8: GPCR-Group
This group is found only in K562 cells.
GPCR-Group: This group is found only in K562 cells. It consists of the
elements PEP, GSK3, ERbB2, small G-proteins, Rac, Nck-2, Caspase-
6, Gq, LynA and Gene AQP 7. If Csk, GPCR and EGFR are added
to the group, then many elements are connected with each other.
3.3.2 Investigating the network for distinct time-points
Abl-containing groups with 388 elements: The previously mentioned
ER-α-Group, the talin group and the GPCR-group are part of this
group. All elements of this group achieve their final value fast and
keep it throughout the 1st four time points.
• Abl= ‘+’ and effects many elements of this group.
• The value of Abl is supported by pRb= ‘-’, an inhibitor of Abl.
The reason for reduced pRb activity cannot be calculated ex-
actly by the model. One possible cause might be RB gene= ‘-’,
mediated via ATF-2.
• ERK being ‘-’ might be important to set genes regulated by ER-α
to ‘-’.
• Interestingly EpoR has increased activity in these calculations
but the behaviour of most of its downstream elements is domi-
nated by another process. Therefore, the elements that get acti-
vated by EpoR, for example Jak 2, Stat 5, Vav, Grb-2, Shc, Pi3K
and PLCγ, have a reduced activity. The reason might be reduced
activity of c-Kit, due to inhibition by SHP-1 or SHP-2.
• EpoR leads to Fes= ‘+’ and subsequently to STAT5a= ‘+’.
3.3 K562 cells treated with Epo 66
Figure 3.9: Network around Abl
Differences between the 1st and 2nd timepoint
• ATF-2= ‘+’ leads to Gene RB= ‘+’ and subsequently to Abl= ‘-’.
PDK1 and AKT-1 propagate the value ‘-’ further into the network.
This results among other things in Caspases-3= ‘+’ and Caspase-6=
‘+’.
• The network has a positive feedback cycle solely consisting of acti-
vating reactions that are build of Erk, FTase, Ras, Raf , MEK, Erk.
The cycle leads via multiple steps to a ‘+’ of the Genes Bcl-2, TNF-α,
SLC9A3R1, Ps2, c-fos, Tf, TGFalpha, PTMA and HSP27.
Differences between the 2nd and 3rd timepoint
• Gene RB= ‘-’ reversing all effects described in the first part of the
previous section.
• The previously discovered cycle is found again in this network, but
with inverted sign. The coupling between cycle members is much
weaker, therefore the cycle might not be active any more.
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3.4 Sensitivity analysis
The method described in section 2.3.2 was applied on the measurements for
untreated CD34+ cells to identify the molecules, that have a high influence
on overall system dynamics. The Transpath network is adjusted to the
CD34+ network by removing unexpressed proteins.
As exemplified in figure 3.10 for PDK1 the effect on the difference in net-
work size induced by expression/not expression of PDK1 depends strongly
on the inhibition probability. If the inhibition probability is extremely low
alternative connections lead to a narrow distribution of possible network
sizes and most networks are big. For intermediate inhibition levels the dis-
tribution is very broad and gets narrow again for high inhibition probabili-
ties. This is consistent with the example shown in section 2.3.2, where for
Prob≈ 1 or Prob≈ 0, the probabilities increase strongly in favour of one
of the extreme network, whereas intermediate values of Prob increase the
number of different networks, that have to be considered.
The average ‘Differences in Network Size’ and average ‘Differences in
Network Behaviour’ for the treated elements for different inhibition proba-
bilities are shown in figure 3.11. Most curves are monotonous, but this is
not the case for all of them. The results can be explained by two effects:
Redundancy : For low inhibition probabilities many molecules are con-
nected with each other among multiple, different paths, if a single
molecule (e.g. the examined one) is removed, then the network, does
not change drastically, because of alternative connections. This leads
to low Values of ‘Difference in Network Size’ and ‘Difference in Net-
work behaviour’.
Reachability : A molecule far away from EpoR, requires a signal that
has passed other molecules. If this molecules are completely inhib-
ited, then the signal does not reach the molecule far away from EpoR,
hence molecules afar from EpoR, require low inhibition probabilities
to obtain high values.
The relation between ‘redundancy’ and ‘reachability’ determines, where the
maximum of a molecule is found in figure 3.11.
Some elements like Pi3K, PIP3, Akt receive high values. This are the
molecules that are considered to have strong influence on EpoR induced
hematopoietic differentiation. Differences between the network obtained for
Cd34+ cells and K562 cells are small (figure 3.12). This may indicate, that
changed dynamic is more important for CML, than changed topology.
Ranking the proteins by the method described in 2.3.2 shows that Pi3K,
Lyn and PIP3 have the highest values as shown in table 3.2. As described
in section 2.3.2 the Factor used to rank the molecules, is basically a number
showing ‘Difference in Network Size’ and ‘Difference in Network Behaviour’
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Molecule Name Factor for NW Size Factor for NW Behaviour
AKT 6.07 2.92
PIP3 4.22 3.79
Pi3K 4.17 3.94
Lyn 2.91 4.64
Caspase-3 2.24 2.26
Gβ:Gγ 2.07 1.25
ERK 2.03 2.32
Syk 1.96 2.65
DAG 1.80 1.50
Jak1 1.54 1.67
Fyn 1.26 1.62
Cdc42 1.22 1.63
Ras 1.16 2.03
p38 1.13 2.13
RhoA 1.12 1.43
SLP-65 1.09 1.30
Src 1.04 1.18
SLP-76 1.01 1.17
p38α - 1.04
Table 3.2: Ranking of molecules
The values obtained for ‘Difference in Network Size’ and ‘Difference in
Network Behaviour’, for each value of Prob, are summarised into single
value, shown here. Most molecules with high ‘Factor for NW Size’ have
also a high ‘Factor for NW Behaviour’.
averaged over all probabilities Prob, divided by the average standard devia-
tion, for each molecule.
3.4 Sensitivity analysis 69
(a) Histogram
(b) Histo
(c) Histogram
Figure 3.10: Histograms for PDK1
The histograms show, that the network distribution, approximated by the
distribution of network sizes, depends strongly on inhibition probability
Prob.
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(a) The figure shows that most calculated ‘Differences in Network Size’ accumulate at the
lower part of the graph. Few outliers can be found easily: Akt has at low probability
of inhibition a value of 39 then this value increases till an inhibition probability of 0.4 is
reached and finally declines for high inhibition probabilities. In contrast to this Lyn, Syk,
PIP3 and Pi3K receive high values for high inhibition probabilities and lower ones for low
ones.
(b) Two groups can be distinguished easily, one group consisting of Lyn, Syk, PIP3 has
high values for high inhibition probabilities that decrease fast. The other group consists
of Pi3K and DAG, whose values peak at an intermediate inhibition probability.
Figure 3.11: Differences for CD34+ cells.
3.4 Sensitivity analysis 71
Figure 3.12: Difference between K562 cells and CD34+ cells
The calculated differences in network size for treated elements between the
Cd34+ and K562 networks are rather small. Only for c-Kit, cyclinB:Cdk1,
PDK1, FAK1, Shc, Bax and Bad(pSer):14-3-3τ , the absolute value exceeds
2.
Chapter 4
Discussion
The aim of this work was to find a method, that is able to work with a few
measured time points and that takes cyclicity and positive feedbacks into
account.
The approach described in chapter 2 is able to do this.
Few time points: The problem arising from the low number of measured
time points is mainly solved by allowing only the reactions that are
found in the database. This restricts the solution space strongly. With-
out this restriction the 33000 measured genes, assuming that every
gene can theoretically interact with any other gene and itself, would
have 1089000000 theoretical reaction possibilities and all networks that
could be build out of these reactions by removing some of them would
have to be checked against the measured data to find the best one. It
is obvious that a time series consisting of 4 or even 10 measurements
does not contain enough information to find the right network. If the
usual restrictions, like limiting the number of interaction partners to
for example three, were used, then the same problem would still re-
main, because the number of combinations for networks would still be
huge.
In Transpath there are 23062 reactions, thus 47220 times fewer reac-
tions than theoretically possible. Because the number of possible net-
works increases exponentially with the number of possible reactions
[95] the number of required measurements decreases drastically.
The advantage is that not so many measurements are required. The
drawback is, that one has to rely on database information and one
might get wrong results if reactions in the database are wrong. Be-
cause the algorithm tries to find the most relevant reactions and thus
ignores some reactions false positive reactions to some degree are not
that critical. More critical are false negative reactions, because the
programme does not search for them.
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Cyclicity: Almost all current Bayesian approaches that infer networks from
data ignore cycles even in differentiation networks despite the knowl-
edge, that positive feedback loops are important for these networks
[73, 26, 94, 93, 61]. Feedbacks are neglected because there are no
theoretical means to deal with them in the Bayesian framework. As
other approaches try to infer structure from data they have a big
search space r(n) =
∑n
i=1(−1)i+1
(
n
i
)
2i(n−i)r(n− i) [101], that cannot
be exhaustively searched, therefore, they need a decomposable system
that can be treated with the Bayes approach and thus cannot consider
feedback loops.
Because, in the method used in this work, the search space is much
more confined, it is possible to calculate many networks and it is the-
oretically feasible to find the best solution by scoring the resulting
network against the data. Because practically just 1000 calculations
are used, one cannot be really sure, that the best solution is found
by the calculations. This problem is solved by taking approx. the 20
best solutions and comparing their similarities. Then the reliability
of feature can be calculated, by the number of its occurrence. For
example, if A activates B in all solutions, then this result is reliable, if
B activates C in 5 of 20 solutions, then this result is less reliable. The
approach allows to identify the well known facts and separate them
from not well known parts of the network and is able to deal with cy-
cles, because decomposition is not necessary. It has the disadvantage
that molecules belonging together might get separated due to many
degrees of freedom and therefore uncertainty in the system (see figure
4.1).
Reactions exceeding thresholds: Usually, Bayesian networks are learn-
ed by looking for correlations between elements among different ex-
perimental conditions or time points. This approach assumes, that
relations between elements remain constant. The shown approach, by
contrast allows, changes in network structure, because it does not use
the experimental data to calculate a priori probabilities, but instead
calculates a network for one time point, that then is allowed to change
using the relations in the database, thus producing a network for an-
other timepoint that than is compared against the calculated data. By
connecting the networks this way changes between the dependencies
of variables over time can be considered.
The approach described in chapter 2 to calculate the network uses the
discrete values ‘0’, ‘+’, ‘+’, ‘uk’,‘PRESENT’ and ‘ABSENT’. The values
‘PRESENT’ and ‘ABSENT’ are used to determine network topology and
are not further checked by the algorithm. The values ‘0’, ‘+’, ‘+’, ‘uk’ are
used to determine how the network works as a whole system.
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(a) If this directed graph and the
information A= ‘+’ and F= ‘+’
are given, then the algorithm could
identify and the following solutions
as good: The one shown here where
all molecule are ‘+’, . . .
(b) . . . this solution where the inter-
action C – D is assumed to be dom-
inant, . . .
(c) . . . the solution where D – B and
. . .
(d) . . . this solution.
(e) All four solutions have the same score and therefore are equally well. The algorithm
knowns for sure, that A = E = F = ‘+’, the values for B, C, D are in 3/4 of the cases
‘+’ and 1/4 of the cases ‘-’, this uncertainty is visualised by the smaller arcs sizes and the
smaller node sizes. If the algorithm shows only absolutely certain values and interactions
then B, C and D are removed from the graph, leading to an unconnected sub-graph.
Figure 4.1: Uncertainties in connections and values
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A false ‘PRESENT’ is not that critical because it is just increasing search
space and reduces the amount of definite conclusions. False ‘ABSENT’
measurements are a source of error. In this work the focus was on developing
a method and therefore, this error source was omitted for simplification
reasons. The resulting mistake could be small, because it was shown that
in technical replicates made with Affymetrix chips the consistence of results
is higher than 95% [102].
However, the problem of false ‘ABSENT’ calls could be solved in two
ways.
1. The first and easiest solution is to leave all proteins in the network
independent whether they are expressed or not, this would result in
an increased number of possible solutions of the network and thus
require more measurements.
2. The second solution is to use different topologies of the treated net-
work, based on the ‘ABSENT’-call information and for example, also
use a number for the probability of this constellation. Then this prob-
ability and the score that was already used to find the best networks
would require a binary operation (e.g. multiplication, addition) to
determine the complete score.
The discrete approach is justified, because it is believed that the hemato-
poietic differentiation is a threshold based process that, after a decision was
made, becomes self-perpetuating. Therefore, it is sufficient to identify the
subsystem being responsible for this self-perpetuating effect. Because only
three real values ‘+’, ‘-’, ‘0’ and a helping value ‘uk’ are used, complex multi-
step processes cannot be calculated by the algorithm. However, the principle
used can be expanded to a system containing more discrete values. The
drawbacks of this would be that the search space increases and, therefore,
the measurements required to restrict the system increase and the precision
of the measurements of the protein status must also increase. It does not
make much sense to use many discrete values if the measurements can give
only the information if a value is ‘IncExpr’ or ‘DecrExpr’.
Discrete systems have the advantage that they require less information
than continuous systems and that their results can be interpreted better.
But they have also drawbacks: For example, the model cannot calculate
what happened before a self-perpetuating cycle was established, the simu-
lation basically starts after the decision on the cell fate was made.
The obtained results are big networks, because the programme leaves
all reactions with high correlation coefficient and a consistent value in the
network. A possible simplification would be to change the algorithm in such
a way that only the minimal network is shown. The disadvantage would
be that potentially important molecules could be omitted. If enough data
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is available the number of possible solutions decreases and the algorithm
would remove inconsistent/unimportant molecules and reactions.
Extraction of functional subnetworks: The identification of functional
subnetworks, described in section 2.2 tries to identify the self sustaining
structures in biological networks. This makes sense, because it is believed
that stochastic effects, that get stabilised, are important for differentiation.
The model works well in the lytic-lysogeny example, where statistic ef-
fects are known to lead to a decision. The calculations identify two stable
solutions, the lytic and the lysogenic, proving that the approach is able to
identify important behaviours of a system based solely on topology and some
starting conditions.
The same approach is used on erythroid differentiation, however, the so-
lution space is much bigger here, therefore, the calculated networks are fil-
tered against the experimentally obtained data, thus only self-perpetuating
structures, that match biological data well, are considered. The obtained
networks are still too big, therefore, they are subdivided in smaller networks
consisting of elements, which have the same dynamic in the calculations.
The results can be tested for biological validity by making measurements
that check if all molecules belonging to one group have the same dynamic of
activity, as predicted by computations. If this is the case then the method
could be used to identify molecules having the similar activity dynamic in
unknown systems. Additionally, molecules with the same dynamic could
be members of one feedback-cycle, having importance in differentiation pro-
cesses or more generally being part of one and the same functional module.
From this point of view it is interesting to note, that a number of groups
found in CD34+ do not exist in K562 cells. Because elements having the
same dynamics over the entire time period of differentiation are put in one
group, absence of a group means, that these elements do not have the same
dynamic any more, although they might still be part of the entire net-
work. The missing groups are: AKT1-Group, Ca2+-Group, IL-6-Group,
c-Kit-Group, IFN-γ-Group, IFN-β-Group. Assuming that these identified
groups of proteins, having the same dynamics throughout all calculated
time points, are essentially something like ‘modules’ or ‘functional units’,
then absence of these groups would suggest non-functional modules. Under
this hypothesis, absence of the IFN-β-Group in K562 cells would indicate,
that this group might be malfunctioning in these cells. Interestingly, IFN-α
is used as a therapy for CML patients, presumably by stimulating immune
response[103, 104]. It may be important that the leukaemia cells themselves
are not stimulated. IFN-α and IFN-β have similar functions, their sequence
difference “may possibly cause different responses to various inducers, or
result in the recognition of different target cell types” [105, 106]. It may
be important that under this situation activity of leukaemia cells is not
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stimulated, which would be coherent with a malfunctioning of this group.
Malfunction of other identified groups might be possible, if their present-
ly known functions are considered:
• IFN-γ whose interaction with other molecules is perturbed in K562
cells is a protein with important immunoregulatory functions, it can
increase antitumor effects of type1 interferons [105].
• The model calculates Akt deregulation. It is known that Bcr-Abl, a
fusion-protein found in many leukaemias (see section 1.1.3) activates
the Pi3K pathway [107] resulting in Akt deregulation [108] as calcu-
lated by the model. Activation of Akt enhances mitosis [109].
The other mentioned malfunctioning modules identified by the calculations
and the additional GPCR-group found only in K562 cells, might also play
important, but presently unknown roles in chronic myeloid leukaemia.
Sensitivity analysis: Jeong et al. [110] emphasize the importance of hubs
for maintenance of network connectivity and functionality. Jeong et al. as-
sume a known and stable topology. In the network, which is developed from
Transpath data, the used network consists of reactions, that were observed in
some systems under certain conditions. In some cases the conditions and the
systems are different from those used in the experiments made for this work,
thus some reactions will not be possible in reality, because, for example, the
parameter-range of the experimental system is such, that proteins are inhib-
ited or some theoretically possible reactions must not be performed due to
thermodynamic constraints. These uncertainties are considered by building
multiple alternative and possible networks and determining the molecules
that are important for the entire set of constructed networks. The different
networks are built by assuming an inhibition probability for proteins that
have the potential to be inhibited. This approach emphasizes the impor-
tance of elements that are close to elements, that are known to be changed
in the network. Elements far away from nodes, whose status is not known
receive lower importance, despite their possibly high connectivity numbers.
This can be seen in figure 3.11 for Akt, that needs a lower inhibition
probability to get connected to EpoR.
The calculated numbers consider a variety of factors:
1. The proximity to EpoR: Molecules far away from EpoR are connected
via molecules that are completely inhibited with a certain probability
and therefore do not get reached in every simulation. As they are not
part in every randomly generated network their overall influence on
the average network behaviour is reduced.
2. The number of interconnections: Highly interconnected molecules have
a higher probability to achieve high values. But a high number of
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interactions is not sufficient to achieve a high difference, because its
effects can be counteracted, by alternative paths and the proximity to
EpoR.
3. The value labelled as Difference in Network Behaviour takes that kind
of information into account and thus gives information beyond the
topology.
Current biological knowledge is consistent with results obtained by the
calculations. As shown in table 3.2, EpoR induced hematopoiesis in CD34
cells should be sensitive to changes in AKT, PIP3, Pi3K, Lyn, Caspase-3,
Gβ:Gγ, ERK, Syk, DAG, Jak1, Fyn, Cdc42, Ras, p38, RhoA, SLP-65, Src,
SLP-76 and p38α, where sensitivity for AKT, PIP3, Pi3K . . . is much higher
(high ranking in table) than for SLP-76 and p38α (low ranking in table).
As published Akt, Pi-3K ERK, p38α and Ras are deregulated in CML
cells [111, 112, 42, 113, 114, 43, 115]. As far as I know the other iden-
tified molecules are not associated mainly with hematopoiesis. Many of
them are well known cellular regulators, also at present not connected with
hematopoiesis, some of them could play a role in hematopoiesis, due to their
presently known cellular functions:
Src, Lyn, Fyn : “The members of the Src kinase family are expressed in
a wide variety of tissues, but some of them such as . . . Lyn are found
primarily in hematopoietic cells . . . Our results indicate that Fyn and
Lyn are efficiently cleaved in their unique region in hematopoietic cells
undergoing apoptosis . . . Thus, cleavage of Fyn and Lyn during in-
duction of apoptosis represents a new mechanism for the regulation
of Src kinases that may have important functional and physiological
consequences”[116].
Caspase-3 : “Caspase-3 is a member of the cysteine protease family, which
plays a crucial role in apoptotic pathways and can be activated by
diverse death-inducing signals, including the chemotherapeutic agents
. . . ”[116].
Syk : “Syk is a protein tyrosine kinase, that is widely expressed in hemato-
poietic cells. It is involved in coupling activated immunreceptors to
downstream signalling events that mediate diverse cellular responses
including proliferation, differentiation and phagocytosis” [116].
DAG : “Dystroglycan is a laminin binding component of the dystrophin-
glycoprotein complex . . . Forms part of the dystrophin-associated pro-
tein complec (DAPC) which may link the cytoskeleton to the extra-
cellular matrix . . . ” [116].
Jak1 : “Janus kinase 1 is a protein tyrosine kinase . . . Numerous aspects
of lymphoid and myeloid cell functions are controlled by a group of
79
ligands termed cytokines, all of each signal through a related set of
receptors. All such receptors are associated with one or more members
of the JAK family.” [117].
Cdc42 : “The protein encoded by this gene is a small GTPase of the Rho-
subfamily . . . Cdc42 regulates anchorage-independent growth and is
necessary for Ras transformation” [116].
RhoA : “Belongs to the small GTPase superfamily . . . Regulates a signal
transduction pathway linking plasma membrane receptors to the as-
sembly of focal adhesions and actin stress fibres” [116].
SLP-65 : SLP-65 is transmembrane receptor protein tyrosine kinase adap-
tor [118] and plays a role in hemocyte development [116].
Considering the size and complexity of the network downstream of EpoR
(see Figure 1.4) a mathematical approach to obtain an overview is necessary.
The ranking of molecules obtained by the symbolic simulations is an impor-
tant aid to experimentalists, showing them the possibly important molecules
of a part of an network in a cell and in this way giving them an overview and
orientation. As the molecules identified as relevant by the model are likely
to contain a lot of information on overall system status, they are a good
starting point for measurements and to perform quantitative simulations of
the over-all system. The importance of the calculated molecules is arising
because of two reasons:
• The molecules play, as shown by comparison to known knowledge, an
important role in hematopoiesis.
• Some identified molecules are hubs, with many connections in the net-
work and thus very likely, contain integrated signals of overall network
status.
The function of some molecules identified by the model, like Lyn, Syk,
DAG . . . , in hematopoiesis is at present not known. These molecules might
be important for hematopoietic differentiation and should be studied further.
The small differences in sensitivity between K562 cells and CD34+ cells
indicate, that differences between these two cell lines are due to changed
dynamics and not because of changed topologies.
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Abbreviations
Abbreviations of genes and molecules are used as in the Tranpath database.
- : The activity of the molecule gets decreased or is already zero.
+ : The activity of the molecule gets increased or is already maximal.
0 : The activity of the molecule is not changed
Abl : Abelson tyrosine kinase
ABSENT : Affymetrix Suite indicates that gene is not expressed.
Acp5 : Acid phosphatase 5
Akt : Protein Kinase B, PKB
AML1 : Acute Myeloid Leukemia 1; alternatively: CBFA2 (Core Binding
Factor A2), PEBPaB (Polyomavirus Enhancer Binding Protein aB)
AQP 7 : Aquaporin 7
AraC : Cytosin Arabinosid
ATF-2 : Activating Transcription Factor 2
B : B lymphocyte
Bcl-2 : B-cell lymphoma-2
BCR : Breakpoint Cluster Region (gene or protein)
βARK-1 : Beta-Adrenergic Receptor Kinase 1; alternatively:
Bmx : Bone marrow kinase
CAD : Caspase-Activated DNAse
CaMKIV : Ca2+/calmodulin-dependent Kinase IV
cAMP : cyclic Adenosin Monophospate
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Cat-2 : Cool-associated tyrosine-phosphorylated protein 2
CBP : CREB-Binding Protein
CCR5 : CC chemokine Receptor 5
CD80 : T Lymphocyte Activation Antigen CD80 Precursor
Cdc42 : Cell division cycle protein 42
Cdk : Cyclin-dependent kinase
cGMP : cyclic Guanosine-Monophosphate
Ci : Cubitus interruptus
CLP : Common Lymphoid Progenitor
CML : Chronic myelogenous leukaemia
CMP : Common Myeloid Progenitor
CMP : Common Multipotent Progenitor
Cos2 : Costal2
Co-Smads : Common mediator Smads
COX2 : Cyclooxygenase 2;
Csk : C-terminal Src-Kinase
CSN2 : Casein beta
CTLA-4 : Cytotoxic T Lymhocyte Antigen 4
DAG : Diacylglycerol
DBN : Dynamic Bayesian Network
DecrExpr : Affymetrix Suite indicates that expression of the gene is de-
creased.
E : Erythrocyte
E. coli : Escherichia Coli
Eb : Erythroblast
EGFR : Epidermal Growth Factor Receptor
Egr3 : Early Growth Response 3
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eNOS : Endothelial Nitric Oxide Synthase
Eos : Eosinophil
EPO : Erythropoietin
EpoR : Erythropoietin Receptor
ER-α : Estrogen Receptor-alpha
ERbB2 : v-Erb-b2 erythroblastic leukaemia viral oncogene homolog 2
ERK : Extracellular signal Regulated Kinase
FAK1 : Focal Adhesion Kinase 1
FcgammaRI : FcgammaReceptor I
FCγRIIB : FcgammaReceptor IIB
fMLP-R : formyl-Methionyl-Leucyl-Phenylalanine Receptor
FTase : Farnesyltransferase
Fu : Fused
G : neutrophil Granulocyte
G6PC : Glucose-6-Phosphatase
GM-CSF : Granulocyte-Macrophage Colony Stimulating Factor
GMP : Granulocyte/Macrophage Progenitor
GPCR : G-Protein Coupled Receptor
Grb-2 : Growth-factor Receptor-Binding Protein 2
GSK3 : Glycogen Synthase Kinase 3
HePTP : Hematopoietic Protein Tyrosine Phosphatase
HLA-D : Human Leukocyte Antigen D
HNF-6 : Hepatocyte Nuclear Factor 6
HNF4A : Hepatocyte Nuclear Factor 4 alpha
HSC : Hematopoietic Stem Cell
HSP27 : Heat Shock Protein 27
IAP : Integrin Associated Protein
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ICAD : Inhibitor of CAD
ICAM-1 : Intercellular Adhesion Molecule 1
IFN : Interferon
IFN-γ : Interferon gamma
IFNRI : Interferon Receptor I
IFNRII : Interferon Receptor II
IKK : IkB Kinase
IL-2 : Interleukin 2
IL-2R : Interleukin 2 Receptor
IL-6R : Interleukin 6 Receptor
ILK : Integrin Linked Kinase
IncrExpr : Affymetrix Suite indicates that expression of the gene is in-
creased.
ins-1 : Insulin 1
InsR : Insulin Receptor
IP-10 : Interferon gamma inducible Protein
IP3 : Inositol-1,4,5-Trisphosphate
IP3R : Inositol-1,4,5-Trisphosphate Receptor
ISG15 : Interferon Stimulated Gene 15
Jak : Janus Kinase
Jak 2: Janus Kinase 2
JNK3 : c-Jun N-Terminal Kinase 3
LXR : Liver X Receptor
Mac : Macrophage
MAP Kinase : Mitogen Activated Pathway Kinase
MCP-1 : Monocyte Chemoattractant Protein 1
MEFV : Mediterranean fever
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Meg : Megakaryocyte
MEK : Mitogen Activated Extracellular Protein Kinase
MEP : Megakaryocyte Erythrocyte Progenitor
Mst : Mammalian Ste20-like Kinase
Nck-2 : Non-Catalytic Region of Tyrosine Kinase Adaptor Protein 2
NF-AT : Nuclear Factor of Activated T-Cells
NHERF-1 : Na+/H+ Exchange Regulatory Factor
NK : Natural Killer cell
NO : Nitric Oxide
NP-complete : Non-deterministic Polynomial time complete
NQO1 : NAD(PH) dehydrogenase quinone 1
NQO1 : Ordinary Differential Equation
Oxt : Oxytocin
P : Platelet
p70S6K : Ribosomal Protein S6 Kinase
PARP : Poly(ADP-ribose)Polymerase
PDK1 : 3’-Phospphatinositide Dependent Kinase 1
PEP : PEST Domain-Enriched Tyrosine Phosphatase
Ph : Philadelphia chromosome
Pi3K : Phosphatidylinositol 3-Kinase
PIAS : Protein Inhibitor of Activated STAT
PIP 2: Phosphatidyl Inositol-4,5-bisphosphate
PIP3 : Phosphatidylinositol-(3,4,5)triphosphat
PITSLRE : p34:cdc2-Related protein kinase
PKA : Protein Kinase A
PKC : Protein Kinase C
PKR : Protein Kinase RNA Regulated
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PLC : Phospholipase C
PLCγ : Phospholipase C gamma
PR : Progesterone Receptor
pRb : Retinoblastome Associated Protein
PRESENT : Affymetrix Suite indicates that gene is expressed.
PRK-2 : PKC Related protein Kinase 2
Ps2 : Preselinin 2
PTMA : Prothymosine Alpha
R-Smads : Receptor regulated Smads
RB : Retinoblastoma 1
Rbp : Retinil Binding Protein 4
Ref-1 : Redox Factor 1
RICS : RhoGAP involved in the beta catenin N cadherin and NMDA re-
ceptor signaling
RSK : Ribosomal S6 Kinase
Sfpi1 : SFFV Proviral Integration 1
SHIP : SH-2-Containing Inositol-5-Phosphatase
SHP-1 : SH-2-Containing Phosphatase 1
SLC9A3R1 : Solute Carrier Family 9 isoform 3 Regulatory factor 1
SLP-65 : SH-2-Domain Containing Leukocyte Adaptor of 65 kDa
SLP-76 : SH-2-Domain Containing Leukocyte Adaptor of 76 kDa
SOCS-3 : Suppressor of Cytokine Signalling 3
SOS : Son of sevenless
SPRR1B : Small Proline-Rich Protein 1B
STAT3 : Signal Transducer and Activator of Transcription 3
STAT5 : Signal Transducer and Activator of Transcription 5
T : T lymphocyte
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Tf : Transferrin
TGFα : Tranforming Growth Factor Alpha
TIMP-1 : Tissue Inhibot of Metalloproteinase 1
TNF : Tumor Necrosis Factor
TNF-α : Tumor Necrosis Factor Alpha
TNFR : Tumor Necrosis Factor Receptor
TPO : Thrombopoietin
uk : The activity of the molecule cannot be calculated exactly, therefore it
is considered to be 50% + and 50 % -.
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